Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
30 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 49(4); October 2017
Prev issue Next issue
Review Article
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Cancer Res Treat. 2017;49(4):851-868.   Published online January 3, 2017
DOI: https://doi.org/10.4143/crt.2016.176
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress. Included studies aimed to prospectively evaluate the efficacy and safety of anti-angiogenic agents in advanced gastric or gastroesophageal junction cancer. Each trial investigated at least one of the following endpoints: overall survival, progression-free survival/time to progression, and/or objective response rate. Our search yielded 139 publications. Forty-two met the predefined inclusion criteria. Included studies reported outcomes with apatinib, axitinib, bevacizumab, orantinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, telatinib, and vandetanib. Second-line therapy with ramucirumab and third-line therapy with apatinib are the only anti-angiogenic agents so far shown to significantly improve survival of patients with advanced gastric cancer. Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis
    Liang Wang, Juyuan Li, Huamin Chen
    Chemotherapy.2024; 69(1): 11.     CrossRef
  • Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
    Ujjawal Sharma, Bunty Sharma, Ambrish Mishra, Anidrisha Sahu, Darin M. Mathkor, Shafiul Haque, Deepika Raina, Seema Ramniwas, Madhu Gupta, Hardeep S. Tuli
    Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
  • Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway
    Huina Wang, Qingzhu Ding, Haihua zhou, Chuanjiang Huang, Guiyuan Liu, Xiaojun Zhao, Zhiyi Cheng, Xiaolan You
    Phytomedicine.2024; 134: 155962.     CrossRef
  • Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
    Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
    Cancer Medicine.2023; 12(7): 7784.     CrossRef
  • Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
    Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisu
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510
    Anica Högner, Salah‐Eddin Al‐Batran, Jens T. Siveke, Mario Lorenz, Prisca Bartels, Kirstin Breithaupt, Peter Malfertheiner, Nils Homann, Alexander Stein, Dietrich Gläser, Ingo Tamm, Axel Hinke, Arndt Vogel, Peter Thuss‐Patience
    International Journal of Cancer.2022; 150(6): 1007.     CrossRef
  • Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer
    Linyan Zhang, Simeng Qin, Liuyi Lu, Li Huang, Shan Li
    The International Journal of Biological Markers.2022; 37(1): 66.     CrossRef
  • Tumor vessel normalization and immunotherapy in gastric cancer
    Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy
    Yanling Ai, Ziyi Zhao, Hengyi Wang, Xiaomei Zhang, Weihan Qin, Yanlei Guo, Maoyuan Zhao, Jianyuan Tang, Xiao Ma, Jinhao Zeng
    Phytotherapy Research.2022; 36(9): 3371.     CrossRef
  • Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
    Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Cai Zhao, Xiangshun Kong, Yao Rong, Weida Zheng, Peng Yu, Yuou Teng
    RSC Advances.2022; 12(34): 21821.     CrossRef
  • Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
    Hardeep Singh Tuli, Ajay Kumar, Seema Ramniwas, Renuka Coudhary, Diwakar Aggarwal, Manoj Kumar, Ujjawal Sharma, Nidarshana Chaturvedi Parashar, Shafiul Haque, Katrin Sak
    Molecules.2022; 27(21): 7653.     CrossRef
  • Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis
    Yanjun Mi, Yongwen Li, Zhuo He, Donghan Chen, Qingqi Hong, Jun You
    Cancer Management and Research.2021; Volume 13: 899.     CrossRef
  • Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
    Shucheng Chen, Lan Yao
    Cancer Chemotherapy and Pharmacology.2021; 88(2): 323.     CrossRef
  • Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC
    Yuanyuan Ma, Xinyu Su, Xin Li, Xiaohui Zhi, Kan Jiang, Jianhong Xia, Hongliang Li, Chen Yan, Liqing Zhou
    Scientific Reports.2021;[Epub]     CrossRef
  • Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
    Xing Kang, En Xu, Xingzhou Wang, Lulu Qian, Zhi Yang, Heng Yu, Chao Wang, Chuanfu Ren, Yizhou Wang, Xiaofeng Lu, Xuefeng Xia, Wenxian Guan, Tong Qiao
    Cell Death & Disease.2021;[Epub]     CrossRef
  • A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
    Lin Li, Yuexian Li, Huawei Zou
    PeerJ.2021; 9: e12356.     CrossRef
  • Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
    Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hi
    Journal of Gastroenterology.2020; 55(6): 627.     CrossRef
  • The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
    Shahrzad S. Fard, Kioomars Saliminejad, Masoud Sotoudeh, Niloofar Soleimanifard, Shaghayegh Kouchaki, Mansour Yazdanbod, Habibollah Mahmoodzadeh, Ardeshir Ghavamzadeh, Reza Malekzadeh, Bahram Chahardouli, Kamran Alimoghaddam, Seyed H. Ghaffari
    Anti-Cancer Agents in Medicinal Chemistry.2020; 19(17): 2097.     CrossRef
  • Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
    Alessandro Rizzo, Veronica Mollica, Angela Dalia Ricci, Ilaria Maggio, Maria Massucci, Fabiola Lorena Rojas Limpe, Francesca Di Fabio, Andrea Ardizzoni
    Future Oncology.2020; 16(2): 4409.     CrossRef
  • S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma
    Chu Zhang, Guang-Mao Yu, Miao Zhang, Dong Liu
    Medicine.2020; 99(1): e18691.     CrossRef
  • An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
    Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianf
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
    Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang, Xin Sun
    International Journal of Clinical Oncology.2020; 25(6): 1195.     CrossRef
  • Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
    Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He, Mingyan E
    Expert Review of Clinical Pharmacology.2020; 13(12): 1423.     CrossRef
  • Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature
    Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka, Masahito Shimizu
    Journal of Gastrointestinal Cancer.2019; 50(3): 556.     CrossRef
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
    Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha, Peush Bajpai
    Journal of Gastrointestinal Cancer.2019; 50(4): 943.     CrossRef
  • Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
    Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, Alberto Russi, Federica Todino, Vincenzo Dadduzio, Francesca Bergamo, Alessandra Anna Prete, Sara Lonardi, Hans Prenen, Angelo Claudio Palozzo, Fotios Loupakis
    Drug Safety.2019; 42(2): 159.     CrossRef
  • VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
    Lian Lian, Xiang-Li Li, Meng-Dan Xu, Xian-Min Li, Meng-Yao Wu, Yan Zhang, Min Tao, Wei Li, Xiao-Ming Shen, Chong Zhou, Min Jiang
    BMC Cancer.2019;[Epub]     CrossRef
  • STUDY OF VEGF-A AND TGF-Β LEVELS IN BIOPTATES OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND MOUTH FLOOR MUCOSA IN POLYCHEMOTHERAPY WITH MONOCLONAL ANTIBODIES – CETUXIMAB
    O. I. Kit, E. M. Frantsiyants, I. V. Neskubina, L. Yu. Vladimirova, A. A. Lyanova, Yu. A. Pogorelova, E. V. Shalashnaya, M. A. Еngibaryan, Yu. S. Sidorenko
    Research and Practical Medicine Journal.2019; 6(3): 20.     CrossRef
  • Tumor progression-dependent angiogenesis in gastric cancer and its potential application
    Hsi-Lung Hsieh, Ming-Ming Tsai
    World Journal of Gastrointestinal Oncology.2019; 11(9): 686.     CrossRef
  • Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
    Guohui Liu, Chunbo Wang, Yunlong He, Mingyan E
    BMC Pharmacology and Toxicology.2019;[Epub]     CrossRef
  • N-methyl-N-nitro-N-nitrosoguanidine-mediated ING4 downregulation contributed to the angiogenesis of transformed human gastric epithelial cells
    Yansu Chen, Rui Fu, Mengdie Xu, Yefei Huang, Guixiang Sun, Lichun Xu
    Life Sciences.2018; 199: 179.     CrossRef
  • GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
    Keshuo Ding, Sheng Tan, Xing Huang, Xiaonan Wang, Xiaocan Li, Rong Fan, Yong Zhu, Peter E. Lobie, Wenbin Wang, Zhengsheng Wu
    Journal of Biological Chemistry.2018; 293(11): 3949.     CrossRef
  • Nanoparticles designed to regulate tumor microenvironment for cancer therapy
    Min Li, Fangrong Zhang, Yujie Su, Jianping Zhou, Wei Wang
    Life Sciences.2018; 201: 37.     CrossRef
  • Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
    Xiaodong Wang, Yu Liu, Yuwen Diao, Ningning Gao, Yanyan Wan, Jingjing Zhong, Huali Zheng, Zhulin Wang, Guangyi Jin
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer
    In-Hwan Kim
    Annals of Surgical Oncology.2018; 25(S3): 749.     CrossRef
  • Identification of Bone Metastasis-associated Genes of Gastric Cancer by Genome-wide Transcriptional Profiling
    Mingzhe Lin, Xin Li, Haizhou Guo, Faxiang Ji, Linhan Ye, Xuemei Ma, Wen Cheng
    Current Bioinformatics.2018; 14(1): 62.     CrossRef
  • Antiangiogenic effects of oridonin
    Lili Tian, Kangjie Xie, Donglai Sheng, Xiaoqing Wan, Guofu Zhu
    BMC Complementary and Alternative Medicine.2017;[Epub]     CrossRef
  • The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
    Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, Hendrina Shipanga, Daniella Munro, Mohammad A. M. Al Mazeedi, Hashim A. M. Almazyadi, Karlien Kallmeyer, Collet Dandara, Michael S. Pepper, M. Iqbal Parker, Kevin Dzobo
    International Journal of Molecular Sciences.2017; 18(7): 1586.     CrossRef
  • Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
    Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
    Scientific Reports.2017;[Epub]     CrossRef
  • Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
    Henrik Nienhüser, Thomas Schmidt
    International Journal of Molecular Sciences.2017; 19(1): 43.     CrossRef
  • 16,901 View
  • 918 Download
  • 45 Web of Science
  • 40 Crossref
Close layer
Original Articles
Laminin Modulates the Stem Cell Population in LM05-E Murine Breast Cancer Cells through the Activation of the MAPK/ERK Pathway
Damián E. Berardi, Diego Raffo, Laura B. Todaro, Marina Simian
Cancer Res Treat. 2017;49(4):869-879.   Published online December 6, 2016
DOI: https://doi.org/10.4143/crt.2016.378
AbstractAbstract PDFPubReaderePub
Purpose
We investigated the effects of laminin on the fraction of cells with self-renewing capacity in the estrogen-dependent, tamoxifen-sensitive LM05-E breast cancer cell line. We also determined whether laminin affected the response to tamoxifen.
Materials and Methods
The LM05-E breast cancer cell line was used as a model for all experiments. Aldehyde dehydrogenase (ALDH) activity, clonogenic and mammosphere assays were performed to measure the effects of laminin on modulation of the stem cell subpopulation. Pluripotent gene expression was analyzed by reverse transcriptase–polymerase chain reaction. The involvement of the mitogen-activated protein kinase (MAPK)/ERK pathway was determined using specific inhibitors. The effects of laminin on the response to tamoxifenwere determined and the involvement of α6 integrin was investigated.
Results
We found that pretreatment with laminin leads to a decrease in cells with the ability to form mammospheres that was accompanied by a decrease in ALDH activity. Moreover, exposure of mammospheres to laminin reduced the capacity to form secondary mammospheres and decreased the expression of Sox-2, Nanog, and Oct-4. We previously reported that 4-OH-tamoxifen leads to an increase in the expression of these genes in LM05-E cells. Treatment with signaling pathway inhibitors revealed that the MAPK/ERK pathway mediates the effects of laminin. Finally, laminin induced tamoxifen resistance in LM05-E cells through α6 integrin.
Conclusion
Our results suggest that the final number of cells with self-renewing capacity in estrogen-dependent breast tumors may result from the combined effects of endocrine treatment and microenvironmental cues.

Citations

Citations to this article as recorded by  
  • The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
    Jie Yuan, Li Yang, Zhi Li, Hua Zhang, Qun Wang, Jun Huang, Bei Wang, Chakrabhavi Dhananjaya Mohan, Gautam Sethi, Geng Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Multiple roles for basement membrane proteins in cancer progression and EMT
    Samarpita Banerjee, Wen-Cheng Lo, Payel Majumder, Debleena Roy, Mimosa Ghorai, Nusrat K. Shaikh, Nishi Kant, Mahipal S. Shekhawat, Vijaykumar Shivaji Gadekar, Suchanda Ghosh, Ercan Bursal, Faris Alrumaihi, Navneet Kumar Dubey, Sanjay Kumar, Danish Iqbal,
    European Journal of Cell Biology.2022; 101(2): 151220.     CrossRef
  • Polymeric immunoglobulin receptor suppresses colorectal cancer through the AKT-FOXO3/4 axis by downregulating LAMB3 expression
    Ding Zhang, Hao Huang, Ting Zheng, Lei Zhang, Binbin Cui, Yanlong Liu, Shiheng Tan, Liyuan Zhao, Tian Tian, Lijing Gao, Qingzhen Fu, Zesong Cheng, Yashuang Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes
    Nicole Mavingire, Petreena Campbell, Jonathan Wooten, Joyce Aja, Melissa B. Davis, Andrea Loaiza-Perez, Eileen Brantley
    Cancer Letters.2021; 500: 64.     CrossRef
  • Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance
    Hassan Yousefi, Mousa Vatanmakanian, Mojdeh Mahdiannasser, Ladan Mashouri, Nikhilesh V. Alahari, Mohammad Rafiee Monjezi, Shahrzad Ilbeigi, Suresh K. Alahari
    Oncogene.2021; 40(6): 1043.     CrossRef
  • Upregulation of LAMB1 via ERK/c-Jun Axis Promotes Gastric Cancer Growth and Motility
    Hana Lee, Won-Jin Kim, Hyeon-Gu Kang, Jun-Ho Jang, Il Ju Choi, Kyung-Hee Chun, Seok-Jun Kim
    International Journal of Molecular Sciences.2021; 22(2): 626.     CrossRef
  • Breast cancer stem cells: A review of their characteristics and the agents that affect them
    Naing L. Shan, Yoosub Shin, Ge Yang, Philip Furmanski, Nanjoo Suh
    Molecular Carcinogenesis.2021; 60(2): 73.     CrossRef
  • Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
    Jing Chen, Runlan Wan, Qinqin Li, Zhenghuan Rao, Yanlin Wang, Lei Zhang, Alexander Tobias Teichmann
    Cancer Cell International.2021;[Epub]     CrossRef
  • Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma
    Fengkai Xu, Zhonghe Liu, Ronghua Liu, Chunlai Lu, Lin Wang, Wei Mao, Qiaoliang Zhu, Huankai Shou, Kunpeng Zhang, Yin Li, Yiwei Chu, Jie Gu, Di Ge
    Cell Communication and Signaling.2020;[Epub]     CrossRef
  • The Tumor Microenvironment as a Driving Force of Breast Cancer Stem Cell Plasticity
    Flavia Fico, Albert Santamaria-Martínez
    Cancers.2020; 12(12): 3863.     CrossRef
  • AhR ligand aminoflavone suppresses α6‐integrin–Src–Akt signaling to attenuate tamoxifen resistance in breast cancer cells
    Petreena S. Campbell, Nicole Mavingire, Salma Khan, Leah K. Rowland, Jonathan V. Wooten, Anna Opoku‐Agyeman, Ashley Guevara, Ubaldo Soto, Fiorella Cavalli, Andrea Irene Loaiza‐Pérez, Gayathri Nagaraj, Laura J. Denham, Olayemi Adeoye, Brittany D. Jenkins,
    Journal of Cellular Physiology.2019; 234(1): 108.     CrossRef
  • Testicular transcriptome alterations in zebrafish (Danio rerio) exposure to 17β-estradiol
    Yao Zheng, Julin Yuan, Shunlong Meng, Jiazhang Chen, Zhimin Gu
    Chemosphere.2019; 218: 14.     CrossRef
  • The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer
    David Rodriguez, Marc Ramkairsingh, Xiaozeng Lin, Anil Kapoor, Pierre Major, Damu Tang
    Cancers.2019; 11(7): 1028.     CrossRef
  • 10,455 View
  • 340 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience
Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim
Cancer Res Treat. 2017;49(4):880-889.   Published online December 12, 2016
DOI: https://doi.org/10.4143/crt.2016.442
AbstractAbstract PDFPubReaderePub
Purpose
The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities.
Materials and Methods
From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTxwas delivered to 172 patients either as a consolidative or a sole modality (group II/III).
Results
During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively.
Conclusion
The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.

Citations

Citations to this article as recorded by  
  • The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
    Dailong Li, Wanqiang Li, Yaqi Pang, Lu Xu, Xinhua Xu
    Medicine.2022; 101(28): e29580.     CrossRef
  • The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer
    Zexu Wang, Baixia Yang, Ping Zhan, Li Wang, Bing Wan
    Journal of Cancer Research and Therapeutics.2022; 18(7): 1910.     CrossRef
  • 44,086 View
  • 260 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
The Prognostic Values of Preoperative Tumor Volume and Tumor Diameter in T1N0 Papillary Thyroid Cancer
Seung Taek Lim, Ye Won Jeon, Young Jin Suh
Cancer Res Treat. 2017;49(4):890-897.   Published online December 13, 2016
DOI: https://doi.org/10.4143/crt.2016.325
AbstractAbstract PDFPubReaderePub
Purpose
The current TNM staging system for papillary thyroid cancer (PTC), which is based on tumor diameter, may not precisely reflect the true tumor burden. Therefore, we investigated whether preoperative tumor volume might more accurately reflect tumor burden and predict prognosis in patients with T1N0 PTC than preoperative tumor diameter.
Materials and Methods
We retrospectively reviewed data from 1,659 patients with T1N0 PTC, and after exclusion, a total of 1,081 patients were ultimately included. Tumor volume (V) was calculated for all patients using preoperative ultrasonography, and patientswere grouped according to tumor diameter (T1a vs. T1b) and tumor volume (V1a vs. V1b). The recurrence-free survival (RFS) rates were then compared for these groups.
Results
The mean follow-up time was 66.12±28.75 months, and 97.2% of the cohort experienced RFS. The optimal volume cut-off was defined as 0.545 cm3. There were no differences in RFS rates between T1a/T1b groups (all ages) and V1a/V1b groups (< 45 years of age). However, ≥ 45-year-old patients in the V1b group had a significantly poorer RFS rate than those in the V1a group. These results were confirmed by multivariate analysis.
Conclusion
Our results indicate that preoperative tumor volume may be more useful for predicting prognosis than tumor diameter in ≥ 45-year-old patients with T1N0 PTC.

Citations

Citations to this article as recorded by  
  • Tumour volume is a predictor of lymphovascular invasion in differentiated small thyroid cancer
    Krishna Vikneson, Tariq Haniff, May Thwin, Ahmad Aniss, Alex Papachristos, Mark Sywak, Anthony Glover
    Endocrine Oncology.2022; 2(1): 42.     CrossRef
  • Prognostic impact of dimensional factors in pT1 gastric cancer
    Chikara Kunisaki, Masazumi Takahashi, Sho Sato, Nobuhiro Tsuchiya, Jun Watanabe, Tsutomu Sato, Kazuhisa Takeda, Yusaku Tanaka, Kohei Kasahara, Takashi Kosaka, Hirotoshi Akiyama, Itaru Endo
    Surgical Oncology.2021; 38: 101584.     CrossRef
  • Total thyroidectomy with and without prophylactic central compartment neck dissection in early papillary thyroid cancer: A comparative study
    Hisham Omran, Ehab Mohammed Ali Fadl, Ahmed Abd El Aal Sultan
    International Journal of Surgery Open.2021; 37: 100411.     CrossRef
  • MicroRNA‑30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7
    Haiyan Guo, Linyun Zhang
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Periostin silencing suppresses the aggressive phenotype of thyroid carcinoma cells by suppressing the Akt/thyroid stimulating hormone receptor axis
    Min Wang, Chunyi Gui, Shenglong Qiu, Jingdong Tang, Zhihai Peng
    Cytotechnology.2018; 70(1): 275.     CrossRef
  • Comparison of incidental versus palpable thyroid nodules presenting for fine‐needle aspiration biopsy
    Ayaka J. Iwata, Arti Bhan, Sharon Lahiri, Amy M. Williams, Andrew R. Taylor, Steven S. Chang, Michael C. Singer
    Head & Neck.2018; 40(7): 1508.     CrossRef
  • Prognostic influence of 3-dimensional tumor volume on breast cancer compared to conventional 1-dimensional tumor size
    Ki-Tae Hwang, Wonshik Han, Sang Mok Lee, Jaewoo Choi, Jongjin Kim, Jiyoung Rhu, Young A Kim, Dong-Young Noh
    Annals of Surgical Treatment and Research.2018; 95(4): 183.     CrossRef
  • Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion
    Jeung Hui Pyo, Sun-Ju Byeon, Hyuk Lee, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Kyoung-Mee Kim, Hyeon Seon Ahn, Kyunga Kim, Yoon-Ho Choi, Jae J. Kim
    Oncotarget.2017; 8(69): 113758.     CrossRef
  • 9,465 View
  • 243 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model
Hyo Joon Jang, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Hee Chul Yang, Dong Kwan Kim
Cancer Res Treat. 2017;49(4):898-905.   Published online January 18, 2017
DOI: https://doi.org/10.4143/crt.2016.312
AbstractAbstract PDFPubReaderePub
Purpose
We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model.
Materials and Methods
Patientswho underwent curative resection for stage IB lung adenocarcinomawere analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence-free survival and overall survival were compared between these two groups.
Results
A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019).
Conclusion
Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.

Citations

Citations to this article as recorded by  
  • Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Zi-Qing Shen, Kun-Peng Feng, Zi-Yao Fang, Tian Xia, Shu Pan, Cheng Ding, Chun Xu, Sheng Ju, Jun Chen, Chang Li, Jun Zhao
    Journal of Cardiothoracic Surgery.2024;[Epub]     CrossRef
  • Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study
    Monica Casiraghi, Francesco Petrella, Claudia Bardoni, Shehab Mohamed, Giulia Sedda, Juliana Guarize, Antonio Passaro, Filippo De Marinis, Patrick Maisonneuve, Lorenzo Spaggiari
    Journal of Clinical Medicine.2023; 12(5): 2081.     CrossRef
  • A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
    Xue Song, Yangyang Xie, Haoran Deng, Fei Yu, Shiqiang Wang, Yafang Lou
    Cancer Control.2023;[Epub]     CrossRef
  • Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
    Ke Zhou, Yaqin Zhao, Linchuan Liang, Jie Cao, Huahang Lin, Zhiyu Peng, Jiandong Mei
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer
    Wei Wang, Fei Teng, Shi Bu, Wei Xu, Qing-Chun Cai, Yue-Quan Jiang, Zhi-Qiang Wang
    Risk Management and Healthcare Policy.2022; Volume 15: 1581.     CrossRef
  • Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
    Matvey M. Tsyganov, Evgeny O. Rodionov, Marina K. Ibragimova, Sergey V. Miller, Olga V. Cheremisina, Irina G. Frolova, Sergey A. Tuzikov, Nikolai V. Litviakov
    Journal of Personalized Medicine.2022; 12(10): 1647.     CrossRef
  • Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort
    Zhichao Zuo, Guochao Zhang, Peng Song, Jing Yang, Shuiting Li, Zhi Zhong, Qinghao Tan, Liming Wang, Qi Xue, Shugeng Gao, Nan Sun, Jie He
    Annals of Surgical Oncology.2021; 28(7): 3941.     CrossRef
  • Drug Regimen for Patients after a Pneumonectomy
    Noheul Kim, Ronny Priefer
    Journal of Respiration.2021; 1(2): 114.     CrossRef
  • Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level
    Khashchuluun Batmunkh, Sukki Cho, Sungwon Yum, Kwhanmien Kim, Sanghoon Jheon
    Interactive CardioVascular and Thoracic Surgery.2020; 30(6): 820.     CrossRef
  • Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion
    Jun Xie, Xian Zhang, Song Hu, Wan-Da Peng, Bin Xu, Yan Li, Su-Juan Zhang, Qing Li, Chong Li
    Journal of Cancer Research and Clinical Oncology.2020; 146(9): 2231.     CrossRef
  • 8,346 View
  • 187 Download
  • 12 Web of Science
  • 10 Crossref
Close layer
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
Cancer Res Treat. 2017;49(4):906-914.   Published online December 26, 2016
DOI: https://doi.org/10.4143/crt.2016.424
AbstractAbstract PDFPubReaderePub
Purpose
Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological characteristics in a high-recurrence risk (node positive, N1) PTC group.
Materials and Methods
Tumor tissue blocks were obtained from 240 surgically resected patients with histologically confirmed stage III/IV (pT3/4 or N1) PTCs. We screened gene fusions using NanoString’s nCountertechnology and mutational analysiswas performed by directDNA sequencing.Data describing the clinicopathological characteristics and clinical courses were retrospectively collected.
Results
Of the 240 PTC patients, 207 (86.3%) had at least one genetic alteration, including BRAF mutation in 190 patients (79.2%), PIK3CA mutation in 25 patients (10.4%), NTRK1/3 fusion in six patients (2.5%), and RET fusion in 24 patients (10.0%). Concomitant presence of more than two genetic alterations was seen in 36 patients (15%). PTCs harboring BRAF mutation were associated with RET wild-type expression (p=0.001). RET fusion genes have been found to occur with significantly higher frequency in N1b stage patients (p=0.003) or groups of patients aged 45 years or older (p=0.031); however, no significant correlation was found between other genetic alterations. There was no trend toward favorable recurrence-free survival or overall survival among patients lacking genetic alterations.
Conclusion
In the selected high-recurrence risk PTC group, most patients had more than one genetic alteration. However, these known alterations could not entirely account for clinicopathological features of high-recurrence risk PTC.

Citations

Citations to this article as recorded by  
  • BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma
    Nobuyuki Bandoh, Takashi Goto, Yasutaka Kato, Akinobu Kubota, Shota Sakaue, Ryuhei Takeda, Shuto Hayashi, Misaki Hayashi, Shogo Baba, Tomomi Yamaguchi-Isochi, Hiroshi Nishihara, Hajime Kamada
    Asian Journal of Surgery.2024; 47(1): 413.     CrossRef
  • FHL1: A novel diagnostic marker for papillary thyroid carcinoma
    Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu
    Pathology International.2024; 74(9): 520.     CrossRef
  • Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC
    Anne Mc Leer, Julie Mondet, Nelly Magnat, Mailys Mersch, Diane Giovannini, Camille Emprou, Anne-Claire Toffart, Nathalie Sturm, Sylvie Lantuéjoul, David Benito
    JTO Clinical and Research Reports.2024; 5(12): 100714.     CrossRef
  • Essential news for clinical practice—thyroid cancer
    Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer
    memo - Magazine of European Medical Oncology.2023; 16(1): 47.     CrossRef
  • A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs
    Abeer Al-Abdallah, Iman Jahanbani, Rola H. Ali, Nabeel Al-Brahim, Jeena Prasanth, Bashayer Al-Shammary, Maie Al-Bader
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • NanoString in the screening of genetic abnormalities associated with thyroid cancer
    Elisabetta Macerola, Anello Marcello Poma, Fulvio Basolo
    Seminars in Cancer Biology.2022; 79: 132.     CrossRef
  • The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations
    Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan
    Journal of Managed Care & Specialty Pharmacy.2022; 28(2): 218.     CrossRef
  • Thyroid cancer incidence disparities among ethnic Asian American populations, 1990–2014
    Alice W. Lee, Roy A. Mendoza, Shehla Aman, Robert Hsu, Lihua Liu
    Annals of Epidemiology.2022; 66: 28.     CrossRef
  • Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization
    Jessica A. Baker, Anthony N. Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J. Marquart, Timothy R. Holzer, Leslie O'Neill Reising, Joel D. Cook, Sameera R. Wijayawardana, Juraj Bodo, Eric D. Hsi, Andrew E. Schade, Gerard J. Oakley
    Archives of Pathology & Laboratory Medicine.2022; 146(3): 351.     CrossRef
  • Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
    Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, Mario Vitale
    Cancers.2020; 12(2): 383.     CrossRef
  • The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis
    Abeer Al-Abdallah, Iman Jahanbani, Heba Mehdawi, Rola H Ali, Nabeel Al-Brahim, Olusegun Mojiminiyi
    Cancer Biology & Therapy.2020; 21(5): 412.     CrossRef
  • Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
    Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
    Thyroid.2020; 30(11): 1589.     CrossRef
  • Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAFV600E and extrathyroidal extension in papillary thyroid carcinoma
    Jia Zhan, Long-hui Zhang, Qing Yu, Chao-lun Li, Yue Chen, Wen-Ping Wang, Hong Ding
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer
    Hongmei Zhang, Kejun Zhang, Liang Ning, Dong Chen, Fengyun Hao, Peng Li
    Bioengineered.2020; 11(1): 1325.     CrossRef
  • High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
    Gerard Anthony M. Espiritu, Joemari T. Malana, Arlie Jean Grace V. Dumasis, Daphne C. Ang
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
    Ali Alqahtani, Hazem S. K. Ayesh, Hafez Halawani
    Cancers.2019; 12(1): 93.     CrossRef
  • Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience
    Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara
    Oncology Letters.2018;[Epub]     CrossRef
  • Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro
    Kai Yu, Tingting Wang, Yujue Li, Chun Wang, Xia Wang, Mei Zhang, Yongmei Xie, Shuangqing Li, Zhenmei An, Tinghong Ye
    Biomedicine & Pharmacotherapy.2017; 92: 403.     CrossRef
  • 10,828 View
  • 370 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Eun Jin Heo, Young Jae Cho, William Chi Cho, Ji Eun Hong, Hye-Kyung Jeon, Doo-Yi Oh, Yoon-La Choi, Sang Yong Song, Jung-Joo Choi, Duk-Soo Bae, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Woong-Yang Park, Byoung-Gie Kim, Jeong-Won Lee
Cancer Res Treat. 2017;49(4):915-926.   Published online January 4, 2017
DOI: https://doi.org/10.4143/crt.2016.322
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research.
Materials and Methods
We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues.
Results
Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023).
Conclusion
PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.

Citations

Citations to this article as recorded by  
  • The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression
    Yoo-Young Lee, Ji-Yoon Ryu, Young-Jae Cho, Ju-Yeon Choi, Jung-Joo Choi, Chel Hun Choi, Jason K. Sa, Jae Ryoung Hwang, Jeong-Won Lee
    Cancer Cell International.2024;[Epub]     CrossRef
  • Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience
    Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Tan
    Journal of Clinical Medicine.2024; 13(9): 2718.     CrossRef
  • Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer
    Byumseok Koh, Ji-Yoon Ryu, Joseph J. Noh, Jae Ryoung Hwang, Jung-Joo Choi, Young-Jae Cho, Jiyoon Jang, Jeong Hyeon Jo, Kwangho Lee, Jeong-Won Lee
    Gynecologic Oncology.2024; 188: 60.     CrossRef
  • Recent advances in lung cancer organoid (tumoroid) research (Review)
    Qiang Zhang, Mingyang Zhang
    Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
  • Patient‐derived xenograft model in colorectal cancer basic and translational research
    Xiaofeng Liu, Zechang Xin, Kun Wang
    Animal Models and Experimental Medicine.2023; 6(1): 26.     CrossRef
  • Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment
    Kenneth K. W. To, Ka M. Cheung, William C. S. Cho
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7217.     CrossRef
  • Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer
    Chi-Son Chang, Ji-Yoon Ryu, June-Kuk Choi, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Joseph J. Noh, Chan Mi Lee, Ji Eun Won, Hee Dong Han, Jeong-Won Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review
    Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, Luiz Fernando Lopes
    Cancers.2023; 15(11): 2990.     CrossRef
  • Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
    Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai
    Cancer Cell International.2023;[Epub]     CrossRef
  • Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer
    佳慧 吴
    Advances in Clinical Medicine.2023; 13(06): 10496.     CrossRef
  • Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma
    Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Ju-Yeon Choi, Jung-Joo Choi, Jason K. Sa, Hyun-Soo Kim, Jeong-Won Lee
    Biomedicine & Pharmacotherapy.2023; 168: 115792.     CrossRef
  • Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model
    Yukari Oda, Kaoru Niimi, Kosuke Yoshida, Satoshi Tamauchi, Akira Yokoi, Yuko Yasui, Yuki Nishiko, Mayu Shibata, Yusuke Shimizu, Masato Yoshihara, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Eiko Yamamoto, Hiroaki Kajiyama
    BMC Cancer.2023;[Epub]     CrossRef
  • Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models
    Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho, Jae-Hoon Kim
    Cancers.2022; 14(3): 829.     CrossRef
  • Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine
    Christine Yee, Kristie-Ann Dickson, Mohammed N. Muntasir, Yue Ma, Deborah J. Marsh
    Frontiers in Bioengineering and Biotechnology.2022;[Epub]     CrossRef
  • Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer
    Jung-In Shim, Ji-Yoon Ryu, Soo Young Jeong, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jason K. Sa, Jeong-Won Lee
    Gynecologic Oncology.2022; 165(2): 270.     CrossRef
  • Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
    Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
    Journal of Clinical Medicine.2022; 11(9): 2606.     CrossRef
  • Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
    Alessandra Ciucci, Marianna Buttarelli, Anna Fagotti, Giovanni Scambia, Daniela Gallo
    Cellular and Molecular Life Sciences.2022;[Epub]     CrossRef
  • Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma
    Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee
    Clinical Cancer Research.2022; 28(17): 3850.     CrossRef
  • Harnessing preclinical models for the interrogation of ovarian cancer
    Tianyu Qin, Junpeng Fan, Funian Lu, Li Zhang, Chen Liu, Qiyue Xiong, Yang Zhao, Gang Chen, Chaoyang Sun
    Journal of Experimental & Clinical Cancer Research.2022;[Epub]     CrossRef
  • The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review
    Lusine Sevinyan, Priyanka Gupta, Eirini Velliou, Thumuluru Kavitha Madhuri
    Cancers.2022; 14(22): 5628.     CrossRef
  • A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report
    Yunke Huang, Jing Xu, Ke Li, Jing Wang, Yilin Dai, Yu Kang
    Cancer Management and Research.2021; Volume 13: 2849.     CrossRef
  • Establishment and preclinical application of a patient-derived xenograft model for uterine cancer
    Soo Young Jeong, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae-Ryoung Hwang, Binnari Kim, Yoo-Young Lee, Hyun-Soo Kim, Jeong-Won Lee
    Gynecologic Oncology.2021; 162(1): 173.     CrossRef
  • Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies
    Paula Cunnea, Christina Fotopoulou, Jennifer Ploski, Fabian Trillsch, Sven Mahner, Mirjana Kessler
    Cancers.2021; 13(13): 3349.     CrossRef
  • Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
    Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
    International Journal of Molecular Sciences.2021; 22(17): 9369.     CrossRef
  • Methodological aspects of creation of patient-derived tumor xenografts
    A S Goncharova, A N Shevchenko, I R Dashkova, A E Anisimov
    Kazan medical journal.2021; 102(5): 694.     CrossRef
  • The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis
    Jinseong Kim, Man Kyu Shim, Young-Jae Cho, Sangmin Jeon, Yujeong Moon, Jiwoong Choi, Jeongrae Kim, Jaewan Lee, Jeong-Won Lee, Kwangmeyung Kim
    Biomaterials.2021; 279: 121189.     CrossRef
  • Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials
    Ana Karen Mendoza-Martinez, Daniela Loessner, Alvaro Mata, Helena S. Azevedo
    Cancers.2021; 13(22): 5745.     CrossRef
  • Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research
    Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M. Moxley, Doris M. Benbrook, Camille Gunderson-Jackson, Maria J. Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz
    Cancers.2021; 13(24): 6288.     CrossRef
  • Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects
    Sharmin Seraj, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn
    Biochemical Pharmacology.2020; 171: 113735.     CrossRef
  • The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance
    Jiahao Shi, Yongyun Li, Renbing Jia, Xianqun Fan
    International Journal of Cancer.2020; 146(8): 2078.     CrossRef
  • KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer
    Jinju Lee, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn
    Journal of Controlled Release.2020; 321: 184.     CrossRef
  • A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma
    Tomoki Yamano, Shuji Kubo, Naohiro Tomita
    Cancer Medicine.2020; 9(10): 3337.     CrossRef
  • Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
    E Sun Paik, Tae-Hyun Kim, Young Jae Cho, Jiyoon Ryu, Jung-Joo Choi, Yoo-Young Lee, Tae-Joong Kim, Chel-Hun Choi, Woo Young Kim, Jason K. Sa, Jin-Ku Lee, Byoung-Gie Kim, Duk-Soo Bae, Hee Dong Han, Hyung Jun Ahn, Jeong-Won Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • A Biobank of Colorectal Cancer Patient-Derived Xenografts
    Suad M. Abdirahman, Michael Christie, Adele Preaudet, Marie C. U. Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M. Sieber, Tracy L. Putoczki
    Cancers.2020; 12(9): 2340.     CrossRef
  • Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis
    Evgeny Chirshev, Nozomi Hojo, Antonella Bertucci, Linda Sanderman, Anthony Nguyen, Hanmin Wang, Tise Suzuki, Emmanuel Brito, Shannalee R. Martinez, Christine Castañón, Saied Mirshahidi, Marcelo E. Vazquez, Pamela Wat, Kerby C. Oberg, Yevgeniya J. Ioffe, J
    Molecular Oncology.2020; 14(11): 2796.     CrossRef
  • Human-Derived Model Systems in Gynecological Cancer Research
    Kadi Lõhmussaar, Matteo Boretto, Hans Clevers
    Trends in Cancer.2020; 6(12): 1031.     CrossRef
  • Spontaneous and Induced Animal Models for Cancer Research
    Anca Onaciu, Raluca Munteanu, Vlad Cristian Munteanu, Diana Gulei, Lajos Raduly, Richard-Ionut Feder, Radu Pirlog, Atanas G. Atanasov, Schuyler S. Korban, Alexandru Irimie, Ioana Berindan-Neagoe
    Diagnostics.2020; 10(9): 660.     CrossRef
  • Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer
    Joseph J. Noh, Myeong-Seon Kim, Young-Jae Cho, Soo-Young Jeong, Yoo-Young Lee, Ji-Yoon Ryu, Jung-Joo Choi, Illju Bae, Zhaoyan Wu, Byoung-Gie Kim, Jae Ryoung Hwang, Jeong-Won Lee
    Pharmaceutics.2020; 12(10): 987.     CrossRef
  • Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures
    Sofia Abreu, Fernanda Silva, Rita Mendes, Teresa F. Mendes, Marta Teixeira, Vítor E. Santo, Erwin R. Boghaert, Ana Félix, Catarina Brito
    Scientific Reports.2020;[Epub]     CrossRef
  • Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer
    Jae Ryoung Hwang, Woo Young Kim, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Myeong-Sun Kim, Ji Hye Kim, E. Sun Paik, Yoo-Young Lee, Hee-Dong Han, Jeong-Won Lee
    Cell Death & Disease.2020;[Epub]     CrossRef
  • Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma
    Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim
    Translational Oncology.2019; 12(2): 269.     CrossRef
  • Platinum Resistance in Ovarian Cancer: Role of DNA Repair
    Giovanna Damia, Massimo Broggini
    Cancers.2019; 11(1): 119.     CrossRef
  • Establishment of patient‐derived xenograft model in ovarian cancer and its influence factors analysis
    Jianfa Wu, Yunxi Zheng, Qi Tian, Ming Yao, Xiaofang Yi
    Journal of Obstetrics and Gynaecology Research.2019; 45(10): 2062.     CrossRef
  • Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
    Seiji Okada, Kulthida Vaeteewoottacharn, Ryusho Kariya
    Cells.2019; 8(8): 889.     CrossRef
  • Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research
    Akira Inoue, Angela K. Deem, Scott Kopetz, Timothy P. Heffernan, Giulio F. Draetta, Alessandro Carugo
    Cancers.2019; 11(9): 1321.     CrossRef
  • Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers
    Jason K. Sa, Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Jihye Kim, Myeong Seon Kim, E. Sun Paik, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yeri Lee, Nam-Gu Her, Yong Jae Shin, Hee Jin Cho,
    Genome Biology.2019;[Epub]     CrossRef
  • The latest animal models of ovarian cancer for novel drug discovery
    Elizabeth Magnotti, Wayne A. Marasco
    Expert Opinion on Drug Discovery.2018; 13(3): 249.     CrossRef
  • Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
    Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi
    Medicines.2018; 5(1): 16.     CrossRef
  • NIRF Optical/PET Dual-Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye
    Caiqin Zhang, Yong Zhao, Ningning Zhao, Dengxu Tan, He Zhang, Xue Chen, Hai Zhang, Jiaze An, Changhong Shi, Mengbin Li
    Contrast Media & Molecular Imaging.2018; 2018: 1.     CrossRef
  • Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
    Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun-Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung-Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae-Hoon Kim, Young Tae Kim, Eun Ji Nam
    Cancer Research and Treatment.2018; 50(3): 956.     CrossRef
  • CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer
    Yeongseon Byeon, Jeong-Won Lee, Whan Soo Choi, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, In Duk Jung, Young-Jae Cho, Hyung Jun Ahn, Byung Cheol Shin, Young Joo Lee, Anil K. Sood, Hee Dong Han, Yeong-Min Park
    Cancer Research.2018; 78(21): 6247.     CrossRef
  • 20,031 View
  • 728 Download
  • 55 Web of Science
  • 51 Crossref
Close layer
Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)
Yeon-Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2017;49(4):927-936.   Published online December 26, 2016
DOI: https://doi.org/10.4143/crt.2016.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy.
Materials and Methods
We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010.
Results
We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).
Conclusion
PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Citations

Citations to this article as recorded by  
  • Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
    Munaser Alamoodi
    European Journal of Breast Health.2024; 20(2): 81.     CrossRef
  • Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
    Lin-Yu Xia, Wei-Yun Xu, Yan Zhao, Sudeep Gupta
    PLOS ONE.2022; 17(6): e0270528.     CrossRef
  • Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
    Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
    The Breast.2022; 66: 54.     CrossRef
  • Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all
    Majd Kayali, Joseph Abi Jaoude, Arafat Tfayli, Nagi El Saghir, Philip Poortmans, Youssef H. Zeidan
    Critical Reviews in Oncology/Hematology.2020; 147: 102880.     CrossRef
  • The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
    Jinli Wei, Yizhou Jiang, Zhimin Shao
    The Breast.2020; 51: 40.     CrossRef
  • The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
    Lei Zhang, Ru Tang, Jia-Peng Deng, Wen-Wen Zhang, Huan-Xin Lin, San-Gang Wu, Zhen-Yu He
    BMC Cancer.2020;[Epub]     CrossRef
  • Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
    Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
    Cancer Research and Treatment.2019; 51(3): 1041.     CrossRef
  • Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
    Jie Zhang, Xiao-Xiao Wang, Jun-Yu Lian, Chuan-Gui Song
    Oncotarget.2019; 10(50): 5245.     CrossRef
  • Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
    Shin-Hyung Park, Jeeyeon Lee, Jeong Eun Lee, Min Kyu Kang, Mi Young Kim, Ho Yong Park, Jin Hyang Jung, Yee Soo Chae, Soo Jung Lee, Jae-Chul Kim
    Radiation Oncology Journal.2018; 36(4): 285.     CrossRef
  • 10,997 View
  • 345 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando
Cancer Res Treat. 2017;49(4):937-946.   Published online January 6, 2017
DOI: https://doi.org/10.4143/crt.2016.423
AbstractAbstract PDFPubReaderePub
Purpose
The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC). This post hoc subgroup analysis assessed the efficacy and safety of neci+GC among East Asian (EA) patients enrolled in the study.
Materials and Methods
All patients received up to six 3-week cycles of gemcitabine (days 1 and 8, 1,250 mg/m²) and cisplatin (day 1, 75 mg/m²). Patients in the neci+GC arm also received necitumumab (days 1 and 8, 800 mg) until disease progression or unacceptable toxicity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from stratified Cox proportional hazards models.
Results
In EA patients, there were improvements for neci+GC (n=43) versus GC (n=41) in OS (HR, 0.805; 95% CI, 0.484 to 1.341) and PFS (HR, 0.720; 95% CI, 0.439 to 1.180), consistent with the results for non-EA patients observed in the present study. The overall safety data were consistent between EA and non-EA patients. A numerically higher proportion of patients experienced serious adverse events (AEs), grade ≥ 3 AEs, and AEs with an outcome of death for neci+GC versus GC in EA patients and EA patients versus non-EA patients for neci+GC.
Conclusion
Although limited by the small sample size and post hoc nature of the analysis, these findings are consistent with those of the overall study and suggest that neci+GC offers a survival advantage and favorable benefit/risk for EA patients with advanced squamous NSCLC.

Citations

Citations to this article as recorded by  
  • Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
    The Hong Phong Nguyen, V. Bharath Kumar, Vinoth Kumar Ponnusamy, Thi Thu Thao Mai, Phuong Tran Nhat, Kathirvel Brindhadevi, Arivalagan Pugazhendhi
    Process Biochemistry.2021; 104: 55.     CrossRef
  • Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis
    Irena Ilic, Sandra Sipetic, Jovan Grujicic, Milena Ilic
    Journal of Oncology Pharmacy Practice.2020; 26(6): 1331.     CrossRef
  • Recent progress in systemic treatment for lung cancer
    Jeffrey W. Clark, Dan L. Longo
    Current Opinion in Pulmonary Medicine.2018; 24(4): 355.     CrossRef
  • Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
    Vincenzo di Noia, Ettore D’Argento, Sara Pilotto, Giulia Grizzi, Mario Caccese, Roberto Iacovelli, Giampaolo Tortora, Emilio Bria
    Expert Opinion on Biological Therapy.2018; 18(9): 937.     CrossRef
  • SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
    Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, Fiona Blackhall, Noor Md Haris, Colin R Lindsay, Raffaele Califano, Mark Voskoboynik, Yvonne Summers, Karen So, Dana Ghiorghiu, Angela W Dymond, Stuart Hossack, Ruth Plummer, Emma Dean
    British Journal of Cancer.2017; 117(7): 938.     CrossRef
  • 10,736 View
  • 398 Download
  • 8 Web of Science
  • 5 Crossref
Close layer
Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
Jae-Hyeon Kim, Jun-Ho Ahn, Michael Lee
Cancer Res Treat. 2017;49(4):947-959.   Published online January 3, 2017
DOI: https://doi.org/10.4143/crt.2016.280
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Intrinsic and acquired resistance limit the therapeutic benefits of inhibitors of oncogenic BRAF in melanoma. To identify microRNAs (miRNAs) associated with resistance to a BRAF inhibitor, we compared miRNA expression levels in three cell lines with different BRAF inhibitor sensitivity.
Materials and Methods
miRNA microarray analysis was conducted to compare miRNA expression levels. Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed to confirm the expression of differentially expressed miRNAs. The cellular effects of miR-1246 were further examined by MTT assay, immunoblotting analysis, cell cycle analysis, flow cytometric assay of apoptosis, and autophagy assay.
Results
The miRNA microarray analysis and qRT-PCR identified five miRNAs (miR-3617, miR-92a-1, miR-1246, miR-193b-3p, and miR-17-3p) with expression that was consistently altered in two BRAF inhibitor-resistant cell lines. Among the five miRNAs, a miR-1246 mimic significantly reduced the antiproliferative effects of the BRAF inhibitor PLX4720 in BRAF inhibitor–resistant A375P (A375P/Mdr) cells, suggesting that miR-1246 upregulation confers acquired resistance to BRAF inhibition. In particular, apoptosis was identified as a major type of cell death in miR-1246–transfected cells; however, necrosis predominated in mimic-control-transfected cells, indicating that the resistance to PLX4720 in miR-1246 mimic-transfected cells is predominantly due to a reduction in necrosis. Furthermore, we found that miR-1246 promoted G2/M arrest through autophagy as a way to escape cell death by necrosis and apoptosis in response to PLX4720. The promotion of BRAF inhibitor resistance by miR-1246 was associated with lowered levels of p-ERK.
Conclusion
These results suggest that miR-1246 may be a potential therapeutic target in melanoma with acquired resistance to BRAF inhibitors.

Citations

Citations to this article as recorded by  
  • Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential
    S. Afsar, Rahamat Unissa Syed, Weam M. A. Khojali, Najat Masood, Mhdia Elhadi Osman, J. Siva Jyothi, Mohd. Abdul Hadi, Amna Abakar Suleiman Khalifa, Nayla Ahmed Mohammed Aboshouk, Hessa Ahmed Alsaikhan, Aljuri Saleh Alafnan, Bushra Abdullah Alrashidi
    Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub]     CrossRef
  • Tumor microenvironment responded naturally extracted FOF1-ATPase loaded chromatophores for antitumor therapy
    Weiyong Hong, Bang Lou, Ying Gao, Hui Zhao, Sanjun Ying, Saicheng Yang, Hanbing Li, Qingliang Yang, Gensheng Yang
    International Journal of Biological Macromolecules.2023; 230: 123127.     CrossRef
  • MITF Downregulation Induces Death in Human Mast Cell Leukemia Cells and Impairs IgE-Dependent Degranulation
    Elizabeth Proaño-Pérez, Laia Ollé, Yanru Guo, Cristina Aparicio, Mario Guerrero, Rosa Muñoz-Cano, Margarita Martin
    International Journal of Molecular Sciences.2023; 24(4): 3515.     CrossRef
  • Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective
    Elisabetta Fratta, Giorgio Giurato, Roberto Guerrieri, Francesca Colizzi, Jessica Dal Col, Alessandro Weisz, Agostino Steffan, Barbara Montico
    Cell Death Discovery.2023;[Epub]     CrossRef
  • BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
    Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, Claudio Tabolacci
    Cancers.2023; 15(16): 4026.     CrossRef
  • METTL3 promotes Non-Small-Cell Lung Cancer Growth and Metastasis by Inhibiting FDX1 Through Copper Death-Associated Pri-miR-21-5p Maturation
    Shuai Qian, Jun Liu, Wenliang Liao, Fengping Wang
    Epigenomics.2023; 15(23): 1237.     CrossRef
  • A Review on the Role of miR-1246 in the Pathoetiology of Different Cancers
    Soudeh Ghafouri-Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, Mohammad Taheri, Mohammad Samadian
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
    Lauretta Levati, Cristian Bassi, Simona Mastroeni, Laura Lupini, Gian Carlo Antonini Cappellini, Laura Bonmassar, Ester Alvino, Simona Caporali, Pedro Miguel Lacal, Maria Grazia Narducci, Ivan Molineris, Federica De Galitiis, Massimo Negrini, Giandomenico
    Cancers.2022; 14(15): 3706.     CrossRef
  • Paradoxical downregulation of LPAR3 exerts tumor-promoting activity through autophagy induction in Ras-transformed cells
    Sung-Hee Hwang, Hye-Gyo Kim, Michael Lee
    BMC Cancer.2022;[Epub]     CrossRef
  • SH3BP2 Silencing Increases miRNAs Targeting ETV1 and Microphthalmia-Associated Transcription Factor, Decreasing the Proliferation of Gastrointestinal Stromal Tumors
    Elizabeth Proaño-Pérez, Eva Serrano-Candelas, Cindy Mancia, Arnau Navinés-Ferrer, Mario Guerrero, Margarita Martin
    Cancers.2022; 14(24): 6198.     CrossRef
  • Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
    Min Seung Lee, So Hyun Lim, Ah-Ran Yu, Chi Yeon Hwang, Insug Kang, Eui-Ju Yeo
    Biology.2021; 10(2): 153.     CrossRef
  • Resistance to Molecularly Targeted Therapies in Melanoma
    Meet Patel, Adam Eckburg, Shahina Gantiwala, Zachary Hart, Joshua Dein, Katie Lam, Neelu Puri
    Cancers.2021; 13(5): 1115.     CrossRef
  • Learning from Embryogenesis—A Comparative Expression Analysis in Melanoblast Differentiation and Tumorigenesis Reveals miRNAs Driving Melanoma Development
    Lisa Linck-Paulus, Lisa Lämmerhirt, Daniel Völler, Katharina Meyer, Julia C. Engelmann, Rainer Spang, Norbert Eichner, Gunter Meister, Silke Kuphal, Anja Katrin Bosserhoff
    Journal of Clinical Medicine.2021; 10(11): 2259.     CrossRef
  • METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246
    Xuehan Bi, Xiao Lv, Dajiang Liu, Hongtao Guo, Guang Yao, Lijuan Wang, Xiaolei Liang, Yongxiu Yang
    Cell Death Discovery.2021;[Epub]     CrossRef
  • Choosing The Right Animal Model for Renal Cancer Research
    Paweł Sobczuk, Anna Brodziak, Mohammed Imran Khan, Stuti Chhabra, Michał Fiedorowicz, Marlena Wełniak-Kamińska, Kamil Synoradzki, Ewa Bartnik, Agnieszka Cudnoch-Jędrzejewska, Anna M. Czarnecka
    Translational Oncology.2020; 13(3): 100745.     CrossRef
  • Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma
    Sara Carpi, Beatrice Polini, Stefano Fogli, Adriano Podestà, Erkko Ylösmäki, Vincenzo Cerullo, Antonella Romanini, Paola Nieri
    Expert Review of Molecular Diagnostics.2020; 20(1): 19.     CrossRef
  • Autophagy inhibition in 3T3-L1 adipocytes breaks the crosstalk with tumor cells by suppression of adipokine production
    Sung-Hee Hwang, Michael Lee
    Animal Cells and Systems.2020; 24(1): 17.     CrossRef
  • Roles of S100 family members in drug resistance in tumors: Status and prospects
    Xin Hua, Hongming Zhang, Jinfang Jia, Shanshan Chen, Yue Sun, Xiaoli Zhu
    Biomedicine & Pharmacotherapy.2020; 127: 110156.     CrossRef
  • MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
    Maria Letizia Motti, Michele Minopoli, Gioconda Di Carluccio, Paolo Antonio Ascierto, Maria Vincenza Carriero
    International Journal of Molecular Sciences.2020; 21(12): 4544.     CrossRef
  • Circulating miRNAs in Small Extracellular Vesicles Secreted by a Human Melanoma Xenograft in Mouse Brains
    Loredana Guglielmi, Marta Nardella, Carla Musa, Ingrid Cifola, Manuela Porru, Beatrice Cardinali, Ilaria Iannetti, Chiara Di Pietro, Giulia Bolasco, Valentina Palmieri, Laura Vilardo, Nicolò Panini, Fabrizio Bonaventura, Massimiliano Papi, Ferdinando Scav
    Cancers.2020; 12(6): 1635.     CrossRef
  • MiR‐1246 promotes anti‐apoptotic effect of mini‐αA in oxidative stress‐induced apoptosis in retinal pigment epithelial cells
    Qianyin Chen, Huimin Lin, Xuan Deng, Shengnan Li, Jinglin Zhang
    Clinical & Experimental Ophthalmology.2020; 48(5): 682.     CrossRef
  • Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
    Ilaria Proietti, Nevena Skroza, Nicoletta Bernardini, Ersilia Tolino, Veronica Balduzzi, Anna Marchesiello, Simone Michelini, Salvatore Volpe, Alessandra Mambrin, Giorgio Mangino, Giovanna Romeo, Patrizia Maddalena, Catherine Rees, Concetta Potenza
    Cancers.2020; 12(10): 2801.     CrossRef
  • The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma
    Luigi Fattore, Rita Mancini, Paolo Antonio Ascierto, Gennaro Ciliberto
    Expert Opinion on Therapeutic Targets.2019; 23(1): 53.     CrossRef
  • A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response
    Ryan K. van Laar, Mitchel T. Lincoln, Barton J. van Laar
    Melanoma Research.2019; 29(1): 19.     CrossRef
  • A three plasma microRNA signature for papillary thyroid carcinoma diagnosis in Chinese patients
    Zhiyan Wang, Jinru Lv, Xuan Zou, Zebo Huang, Huo Zhang, Qingxie Liu, Lin Jiang, Xin Zhou, Wei Zhu
    Gene.2019; 693: 37.     CrossRef
  • The origin of exosomal miR-1246 in human cancer cells
    Yi-Fan Xu, Bethany N. Hannafon, Ujjwol Khatri, Amy Gin, Wei-Qun Ding
    RNA Biology.2019; 16(6): 770.     CrossRef
  • Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis
    Jun-Ho Ahn, Sung-Hee Hwang, Hyun-Soo Cho, Michael Lee
    Biomolecules & Therapeutics.2019; 27(3): 302.     CrossRef
  • MicroRNA heterogeneity in melanoma progression
    Anita Thyagarajan, Kenneth Y. Tsai, Ravi P. Sahu
    Seminars in Cancer Biology.2019; 59: 208.     CrossRef
  • miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
    Simona Caporali, Adriana Amaro, Lauretta Levati, Ester Alvino, Pedro Miguel Lacal, Simona Mastroeni, Federica Ruffini, Laura Bonmassar, Gian Carlo Antonini Cappellini, Nadia Felli, Alessandra Carè, Ulrich Pfeffer, Stefania D’Atri
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • MicroRNA-1246 regulates the radio-sensitizing effect of curcumin in bladder cancer cells via activating P53
    Ran Xu, Huabing Li, Shuiqing Wu, Jian Qu, Haiyan Yuan, Yangang Zhou, Qiong Lu
    International Urology and Nephrology.2019; 51(10): 1771.     CrossRef
  • The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers
    Douglas Donnelly, Phyu P. Aung, George Jour
    Seminars in Cancer Biology.2019; 59: 165.     CrossRef
  • Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors
    Sung-Hee Hwang, Jun-Ho Ahn, Michael Lee
    Genes & Genomics.2019; 41(11): 1273.     CrossRef
  • Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway
    Shaimaa A. Gad, Hamdy E. A. Ali, Rofaida Gaballa, Rania M. Abdelsalam, Mourad Zerfaoui, Hamed I. Ali, Salwa H. Salama, Sanaa A. Kenawy, Emad Kandil, Zakaria Y. Abd Elmageed
    Scientific Reports.2019;[Epub]     CrossRef
  • The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
    Xiao Liu, Jinfeng Wu, Haihong Qin, Jinhua Xu
    Targeted Oncology.2018; 13(4): 437.     CrossRef
  • Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor
    Xiaohui Wang, Huajun Qu, Yinghe Dong, Guozhi Wang, Yuchen Zhen, Linxia Zhang
    Cancer Biomarkers.2018; 23(1): 67.     CrossRef
  • Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4
    Li-Jun Mo, Man Song, Qiao-Hua Huang, Hua Guan, Xiao-Dan Liu, Da-Fei Xie, Bo Huang, Rui-Xue Huang, Ping-Kun Zhou
    British Journal of Cancer.2018; 119(4): 492.     CrossRef
  • An oasis in the desert of cancer chemotherapeutic resistance: The enlightenment from reciprocal crosstalk between signaling pathways of UPR and autophagy in cancers
    Yuhang Zhang, Xianjun Qu, Lingfan Jiang
    Biomedicine & Pharmacotherapy.2017; 92: 972.     CrossRef
  • 12,127 View
  • 397 Download
  • 37 Web of Science
  • 37 Crossref
Close layer
Neurocognitive and Psychological Functioning of Children with an Intracranial Germ Cell Tumor
Younghee Park, Eun-Seung Yu, Boram Ha, Hyeon-Jin Park, Jong-Heun Kim, Joo-Young Kim
Cancer Res Treat. 2017;49(4):960-969.   Published online January 4, 2017
DOI: https://doi.org/10.4143/crt.2016.204
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to investigate the neurocognitive functioning of children with intracranial germ cell tumor (IGCT) prior to receiving proton beam therapy (PBT), and to identify differential characteristics of their neurocognitive functioning depending on tumor location. As a secondary object of this study, neurocognitive functions were followed up at 1-2 years after PBT to examine early post-treatment changes.
Materials and Methods
Between 2008 and 2014, 34 childrenwith IGCT treatedwho received PBT atNational Cancer Center, Korea were enrolled in this study. Standardized neurocognitive tests of intelligence, memory, and executive functioningwere performedwith baseline psychological assessments using the Child Behavior Checklist (CBCL). Follow-up assessments after PBTwere conducted in 20 patients (T2). The results were analyzed based on the locations of tumors, which included the suprasellar, pineal gland, basal ganglia, and bifocal regions.
Results
The neurocognitive function of IGCT patients was significantly lower than that of the normal population in performance intelligence quotient (p=0.041), processing speed (p=0.007), memory (p < 0.001), and executive functioning (p=0.010). Patients with basal ganglia tumors had significantly lower scores for most domains of neurocognitive functioning and higher scores for CBCL than both the normal population and patients with IGCT in other locations. There was no significant change in neurocognitive function between T1 and T2 for all types of IGCT patients in first 1-2 years after PBT.
Conclusion
Tumor location significantly affects the neuropsychological functioning in patients with IGCT. Neuropsychological functioning should be closely monitored from the time of diagnosis in IGCT patients.

Citations

Citations to this article as recorded by  
  • Neurocognitive Dysfunction After Treatment for Pediatric Brain Tumors: Subtype-Specific Findings and Proposal for Brain Network-Informed Evaluations
    Charlotte Sleurs, Paul Fletcher, Conor Mallucci, Shivaram Avula, Thankamma Ajithkumar
    Neuroscience Bulletin.2023; 39(12): 1873.     CrossRef
  • Proton therapy for pediatric diencephalic tumors
    Adam J. Grippin, Susan L. McGovern
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Neurocognitive and psychological functioning of pediatric brain tumor patients undergoing proton beam therapy for three different tumor types
    Sang Hee Youn, Boram Ha, Eun‐Hee Lee, Boram Park, Song Ei Yang, Eun‐Seung Yu, Joo‐Young Kim
    Pediatric Blood & Cancer.2022;[Epub]     CrossRef
  • The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors
    Hideo Nakamura, Hirokazu Takami, Takaaki Yanagisawa, Toshihiro Kumabe, Takamitsu Fujimaki, Yoshiki Arakawa, Katsuyuki Karasawa, Keita Terashima, Hideaki Yokoo, Kohei Fukuoka, Yukihiko Sonoda, Kaori Sakurada, Yohei Mineharu, Toshinori Soejima, Motoaki Fuji
    Neuro-Oncology.2022; 24(4): 503.     CrossRef
  • Hyperbaric Oxygen Therapy as a Complementary Treatment in Glioblastoma—A Scoping Review
    Diogo Alpuim Costa, Mafalda Sampaio-Alves, Eduardo Netto, Gonçalo Fernandez, Edson Oliveira, Andreia Teixeira, Pedro Modas Daniel, Guilherme Silva Bernardo, Carla Amaro
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Neurobehavioral Impairment in Pediatric Brain Tumor Survivors: A Meta-Analysis
    Yuliang Wang, Anthony Pak Yin Liu, Tatia Mei-Chun Lee, Wilfred Hing Sang Wong, Daniel Yee Tak Fong, Lok Kan Leung, Matthew Ming Kong Shing, Dennis Tak-Loi Ku, Godfrey Chi-Fung Chan, Winnie Wan-Yee Tso
    Cancers.2022; 14(13): 3269.     CrossRef
  • Socio-behavioral dysfunction in disorders of hypothalamic-pituitary involvement: The potential role of disease-induced oxytocin and vasopressin signaling deficits
    Lauren Clarke, Olena Zyga, Psalm L. Pineo-Cavanaugh, Michael Jeng, Nancy J. Fischbein, Sonia Partap, Laurence Katznelson, Karen J. Parker
    Neuroscience & Biobehavioral Reviews.2022; 140: 104770.     CrossRef
  • Neurocognitive impairment following proton therapy for paediatric brain tumour: a systematic review of post-therapy assessments
    Noorazrul Yahya, Hanani Abdul Manan
    Supportive Care in Cancer.2021; 29(6): 3035.     CrossRef
  • Behavior Disorder and Social Function Impairment in Children with Basal Ganglia Germ Cell Tumors
    Wenyi Lv, Jin Feng, Li Chen, Shuai Liu, Xiaoguang Qiu
    Neuropsychiatric Disease and Treatment.2021; Volume 17: 91.     CrossRef
  • Comparison on epidemiology, tumor location, histology, and prognosis of intracranial germ cell tumors between Mayo Clinic and Japanese consortium cohorts
    Hirokazu Takami, Avital Perry, Christopher S. Graffeo, Caterina Giannini, Yoshitaka Narita, Yoichi Nakazato, Nobuhito Saito, Ryo Nishikawa, Masao Matsutani, Koichi Ichimura, David J. Daniels
    Journal of Neurosurgery.2021; 134(2): 446.     CrossRef
  • Functional Outcomes of Germ Cell Tumors
    Masayuki Kanamori, Ryuta Saito, Teiji Tominaga
    Japanese Journal of Neurosurgery.2020; 29(4): 270.     CrossRef
  • Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults
    Jordan Wong, Karen Goddard, Normand Laperriere, Jennifer Dang, Eric Bouffet, Ute Bartels, David Hodgson, Scott Tyldesley, Juliette Hukin, Sylvia Cheng, Philippe L. Bedard, Andrea C. Lo
    Journal of Neuro-Oncology.2020; 149(3): 523.     CrossRef
  • The impact of neuroimaging advancement on neurocognitive evaluation in pediatric brain tumor survivors: A review
    Juan Fan, Ronald Milosevic, Jiefei Li, Jianjun Bai, Yuqi Zhang
    Brain Science Advances.2019; 5(2): 117.     CrossRef
  • The impact of neuroimaging advancement on neurocognitive evaluation in pediatric brain tumor survivors: A review
    Juan Fan, Ronald Milosevic, Jiefei Li, Jianjun Bai, Yuqi Zhang
    Brain Science Advances.2019; 5(2): 117.     CrossRef
  • Cognitive Profile of Children With Intracranial Germ Cell Tumor According to Tumor Location
    Virginie Coutinho, Georges Dellatolas, Clemence Castaignede-Lalande, Audrey Longaud-Vales, Virginie Kieffer, Lea Guerrini-Rousseau, Jacques Grill, Dominique Valteau-Couanet, Christelle Dufour
    Journal of Pediatric Hematology/Oncology.2018; 40(7): e424.     CrossRef
  • 8,377 View
  • 295 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study
Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon-Joo Kim, Eun Sook Lee, Keun Seok Lee, Han-Sung Kang, In Hae Park, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2017;49(4):970-980.   Published online January 4, 2017
DOI: https://doi.org/10.4143/crt.2016.382
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.
Materials and Methods
We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.
Results
A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.
Conclusion
We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

Citations

Citations to this article as recorded by  
  • Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
    Nalee Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Kyung Hwan Shin, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Yong Bae Kim
    International Journal of Radiation Oncology*Biology*Physics.2024;[Epub]     CrossRef
  • The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
    Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
    Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
    BMC Cancer.2022;[Epub]     CrossRef
  • What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
    Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992.     CrossRef
  • Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation
    Shin-Hyung Park, Jae-Chul Kim
    Radiation Oncology Journal.2020; 38(1): 44.     CrossRef
  • Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era
    Fabio Corsi, Luca Sorrentino, Sara Albasini, Daniela Bossi, Carlo Morasso, Laura Villani, Marta Truffi
    Medicine.2020; 99(35): e21721.     CrossRef
  • Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy
    Xuran Zhao, Yu Tang, Shulian Wang, Yong Yang, Hui Fang, Jianyang Wang, Hao Jing, Jianghu Zhang, Guangyi Sun, Siye Chen, Jing Jin, Yongwen Song, Yueping Liu, Bo Chen, Shunan Qi, Ning Li, Yuan Tang, Ningning Lu, Hua Ren, Yexiong Li
    Radiation Oncology.2020;[Epub]     CrossRef
  • Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
    Haeyoung Kim, Heejung Kim, Won Park, Jong Yun Baek, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Jin Ho Kim, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Jee Suk Chang,
    Cancers.2020; 12(11): 3261.     CrossRef
  • Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
    Jaeho Kim, Won Park, Jin Kim, Doo Choi, Yeon-Joo Kim, Eun Lee, Kyung Shin, Jin Kim, Kyubo Kim, Yong Kim, Sung-Ja Ahn, Jong Lee, Mison Chun, Hyung-Sik Lee, Jung Kim, Jihye Cha
    Cancers.2019; 11(5): 680.     CrossRef
  • Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
    Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
    Cancer Research and Treatment.2018; 50(4): 1316.     CrossRef
  • 10,277 View
  • 319 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
Cancer Res Treat. 2017;49(4):981-989.   Published online January 6, 2017
DOI: https://doi.org/10.4143/crt.2016.522
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better controlling occult metastases. We conducted two parallel randomized phase II studies to incorporate erlotinib or irinotecan-cisplatin (IP) into CCRT for stage III NSCLC depending on epidermal growth factor receptor (EGFR) mutation status.
Materials and Methods
Patients with EGFR-mutant tumors were randomized to receive three cycles of erlotinib first and then either CCRT with erlotinib followed by erlotinib (arm A) or CCRT with IP only (arm B). Patients with EGFR unknown or wild-type tumors were randomized to receive either three cycles of IP before (arm C) or after CCRT with IP (arm D).
Results
Seventy-three patients were screened and the study was closed early because of slow accrual after 59 patients were randomized. Overall, there were seven patients in arm A, five in arm B, 22 in arm C, and 25 in arm D. The response rate was 71.4% and 80.0% for arm A and B, and 70.0% and 73.9% for arm C and D. The median overall survival (OS) was 39.3 months versus 31.2 months for arm A and B (p=0.442), and 16.3 months versus 25.3 months for arm C and D (p=0.050). Patients with sensitive EGFR mutations had significantly longer OS than EGFR-wild patients (74.8 months vs. 25.3 months, p=0.034). There were no unexpected toxicities.
Conclusion
Combined-modality treatment by molecular diagnostics is feasible in stage III NSCLC. EGFR-mutant patients appear to be a distinct subset with longer survival.

Citations

Citations to this article as recorded by  
  • Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
    Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
    Lung Cancer.2024; 187: 107414.     CrossRef
  • The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow, Pasi A Jänne, Mari Mino-Kenudson, Scott Swanson, Cameron D Wright, David Kozono, Paul Marcoux, Zofia Piotrowska, Lecia V Sequist, Henning Willers
    The Oncologist.2024; 29(7): 609.     CrossRef
  • Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
    Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
    Current Oncology.2024; 31(9): 5121.     CrossRef
  • Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
    Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo
    Expert Review of Anticancer Therapy.2023; 23(9): 913.     CrossRef
  • Peptide-Hydrogel Nanocomposites for Anti-Cancer Drug Delivery
    Farid Hajareh Haghighi, Roya Binaymotlagh, Ilaria Fratoddi, Laura Chronopoulou, Cleofe Palocci
    Gels.2023; 9(12): 953.     CrossRef
  • Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
    Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
    Cancer Science.2022; 113(1): 205.     CrossRef
  • Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
    Ligang Xing, Gang Wu, Luhua Wang, Jiancheng Li, Jianhua Wang, Zhiyong Yuan, Ming Chen, Yaping Xu, Xiaolong Fu, Zhengfei Zhu, You Lu, Chun Han, Tingyi Xia, Conghua Xie, Guang Li, Shenglin Ma, Bing Lu, Qin Lin, Guangying Zhu, Baolin Qu, Wanqi Zhu, Jinming Y
    International Journal of Radiation Oncology*Biology*Physics.2021; 109(5): 1349.     CrossRef
  • A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer
    M. Or, B. Liu, J. Lam, S. Vinod, W. Xuan, R. Yeghiaian-Alvandi, E. Hau
    Scientific Reports.2021;[Epub]     CrossRef
  • Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
    Aruz Mesci, Theodoros Tsakiridis, Anand Swaminath
    Journal of Thoracic Oncology.2021; 16(10): 1607.     CrossRef
  • Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
    Choi Eunsook, Park Sunhee
    Clinical Journal of Nursing Care and Practice.2021; 5(1): 015.     CrossRef
  • Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
    Miguel J Sotelo, José Luis García, Cesar Torres-Mattos, Héctor Milián, Carlos Carracedo, María Ángeles González-Ruiz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago
    World Journal of Clinical Oncology.2021; 12(10): 912.     CrossRef
  • PLGA nanoparticle-reinforced supramolecular peptide hydrogels for local delivery of multiple drugs with enhanced synergism
    Can Wu, Chunlu Wang, Lu Sun, Keming Xu, Wenying Zhong
    Soft Matter.2020; 16(46): 10528.     CrossRef
  • Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials
    Ruifeng Liu, Shihong Wei, Qiuning Zhang, Xueliang Zhang, Hongtao Luo, Jinhui Tian, Yi Li, Long Ge, Xiaohu Wang
    Medicine.2019; 98(29): e16427.     CrossRef
  • Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
    Sanjal Desai, Chul Kim, Irina Veytsman
    Current Oncology Reports.2019;[Epub]     CrossRef
  • 10,164 View
  • 310 Download
  • 14 Web of Science
  • 14 Crossref
Close layer
Risk Factors of Female Breast Cancer in Vietnam: A Case-Control Study
Phuong Dung (Yun) Trieu, Claudia Mello-Thoms, Jennifer K. Peat, Thuan Doan Do, Patrick C. Brennan
Cancer Res Treat. 2017;49(4):990-1000.   Published online February 20, 2017
DOI: https://doi.org/10.4143/crt.2016.488
AbstractAbstract PDFPubReaderePub
Purpose
Rates of women with breast cancer have increased rapidly in recent years in Vietnam, with over 10,000 new patients contracting the disease every year. This study was conducted to identify demographic, reproductive and lifestyle risk factors for breast cancer in Vietnam.
Materials and Methods
Breast density, demographic, reproductive and lifestyle data of 269 women with breast cancer and 519 age-matched controls were collected in the two largest oncology hospitals in Vietnam (one in the north and one in the south). Baseline differences between cases and controls in all women, premenopausal and postmenopausal women were assessed using chi-squared tests and independent t tests. Conditional logistic regressionwas used to derive odds ratios (OR) for factors that had statistically significant associations with breast cancer.
Results
Vietnamesewomenwith breast cancerwere significantly more likely to have a breast density > 75% (OR, 1.7), be younger than 14 years at first menstrual period (OR, 2.2), be postmenopausal (OR, 2.0), have less than three pregnancies (OR, 2.1), and have less than two babies (OR, 1.7). High breast density (OR, 1.6), early age at first menstrual period (OR, 2.6), low number of pregnancies (OR, 2.3), hormone use (OR, 1.8), and no physical activities (OR, 2.2) were significantly associated with breast cancer among premenopausal women, while breast density (OR, 2.0), age at first menstrual period (OR, 1.8), number of pregnancies (OR, 2.3), and number of live births (OR, 2.4) were the risk factors for postmenopausal women.
Conclusion
Breast density, age at first menarche, menopause status, number of pregnancies, number of babies born, hormone use and physical activitieswere significantly associatedwith breast cancer in Vietnamese women.

Citations

Citations to this article as recorded by  
  • Comparative Analysis of Women’s Breast Cancer Survival Time at Three Selected Government Referral Hospitals in Ethiopia’s Amhara Region Using Parametric Shared Frailty Models
    Seid Fentaw, Anteneh Godana, Dawit Abathun, Dessie Melese Chekole
    Breast Cancer: Targets and Therapy.2024; Volume 16: 269.     CrossRef
  • Systematic Review and Meta-Analysis of Lifestyle and Reproductive Factors Associated with Risk of Breast Cancer in Asian Women
    Boon Hong Ang, Soo-Hwang Teo, Weang-Kee Ho
    Cancer Epidemiology, Biomarkers & Prevention.2024; 33(10): 1273.     CrossRef
  • Look how far we have come: BREAST cancer detection education on the international stage
    Phuong Dung (Yun) Trieu, Claudia R. Mello-Thoms, Melissa L. Barron, Sarah J. Lewis
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Information Needs of Patients With Breast Cancer Undergoing Treatment in Vietnam and Related Determinants
    Nguyen Thi SON, Hsin-Tien HSU, Pham Thi Thu HUONG, Truong Quang TRUNG
    Journal of Nursing Research.2023; 31(2): e265.     CrossRef
  • Family history and breast cancer risk for Asian women: a systematic review and meta-analysis
    Heran Wang, Robert J. MacInnis, Shuai Li
    BMC Medicine.2023;[Epub]     CrossRef
  • Exploring the Mental Health Challenges of Women Diagnosed with Breast Cancer in Vietnam: A Qualitative Study
    Ngoc Nguyen Bao, Ngan Thu Tran, Chris Jenkins, Hoang Van Minh, Phuong Tran Bich, Helene Johansson
    Social Work in Public Health.2023; 38(5-8): 416.     CrossRef
  • Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer
    Yingkun Xu, Dan Shu, Meiying Shen, Qiulin Wu, Yang Peng, Li Liu, Zhenrong Tang, Shun Gao, Yuan Wang, Shengchun Liu, Dawei Cui
    Journal of Immunology Research.2022; 2022: 1.     CrossRef
  • Do lifestyle factors influence risk of breast cancer recurrence in Korean women?: a cross-sectional survey
    So-Jung Park, Hye-Ah Yeom
    Korean Journal of Women Health Nursing.2022; 28(2): 145.     CrossRef
  • Menstrual and Reproductive Factors in Association With Breast Cancer Risk in Vietnamese Women: A Case-Control Study
    Oanh Thi Bui, Huong Thanh Tran, Sang Minh Nguyen, Tu Van Dao, Quang Vinh Bui, Anh Tuan Pham, Martha J. Shrubsole, Qiuyin Cai, Fei Ye, Wei Zheng, Hung Nguyen Luu, Thuan Van Tran, Xiao-Ou Shu
    Cancer Control.2022;[Epub]     CrossRef
  • Risk Factors Associated with Breast Cancer among Women in Addis Ababa, Ethiopia: Unmatched Case–Control Study
    Lidia Tolessa, Endalew Gemechu Sendo, Negalign Getahun Dinegde, Assefa Desalew
    International Journal of Women's Health.2021; Volume 13: 101.     CrossRef
  • Trends in breast cancer incidence in Ho Chi Minh City 1996–2015: A registry-based study
    Dung X. Pham, Thao-Quyen H. Ho, Tung D. Bui, Lan T. Ho-Pham, Tuan V. Nguyen, Mohammad R. Akbari
    PLOS ONE.2021; 16(2): e0246800.     CrossRef
  • Mammographic densities of Aboriginal and non-Aboriginal women living in Australia’s Northern Territory
    Kriscia A. Tapia, Gail Garvey, Mark F. McEntee, Mary Rickard, Lorraine Lydiard, Patrick C. Brennan
    International Journal of Public Health.2019; 64(7): 1085.     CrossRef
  • Cancers in Vietnam—Burden and Control Efforts: A Narrative Scoping Review
    Tung Pham, Linh Bui, Giang Kim, Dong Hoang, Thuan Tran, Minh Hoang
    Cancer Control.2019;[Epub]     CrossRef
  • Determinants of breast cancer in Saudi women from Makkah region: a case-control study (breast cancer risk factors among Saudi women)
    Fatmah J. Alsolami, Firas S. Azzeh, Khloud J. Ghafouri, Mazen M. Ghaith, Riyad A. Almaimani, Hussain A. Almasmoum, Rwaa H. Abdulal, Wesam H. Abdulaal, Abdelelah S. Jazar, Sufyan H. Tashtoush
    BMC Public Health.2019;[Epub]     CrossRef
  • Association of overweight and obesity with breast cancer during premenopausal period in Asia: A meta-analysis
    RicvanDana Nindrea, Teguh Aryandono, Lutfan Lazuardi, Iwan Dwiprahasto
    International Journal of Preventive Medicine.2019; 10(1): 192.     CrossRef
  • 10,478 View
  • 461 Download
  • 14 Web of Science
  • 15 Crossref
Close layer
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat. 2017;49(4):1001-1011.   Published online January 13, 2017
DOI: https://doi.org/10.4143/crt.2016.546
AbstractAbstract PDFPubReaderePub
Purpose
This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung cancer (NA-NSCLC).
Materials and Methods
Patientswith advancedNA-NSCLCwho progressed after one ortwo chemotherapy regimens were randomly assigned to a simvastatin (40 mg/day) plus afatinib (40 mg/day) (AS) arm or to an afatinib (A) arm. The primary endpoint was response rate (RR).
Results
Sixty-eight patients were enrolled (36 in the AS arm and 32 in the A arm). The RR was 5.7% (95% confidence interval [CI], 0.7 to 19.2) for AS and 9.4% (95% CI, 2.0 to 25.0) for A (p=0.440). In arms AS and A, the median progression-free survival (PFS) was 1.0 versus 3.6 months (p=0.240) and the overall survival was 10.0 months versus 7.0 months (p=0.930), respectively. Skin rash, stomatitis, and diarrhea were the most common adverse events in both arms. More grade 3 or 4 diarrhea was observed in arm A (18.8% vs. 5.6% in arm AS). In all patients, the median PFS for treatment including afatinib was not correlated with the status of epidermal growth factor receptor (EGFR) mutation (p=0.122), EGFR fluorescence in situ hybridization (p=0.944), or EGFR immunohistochemistry (p=0.976). However, skin rash severity was significantly related to the risk of progression for afatinib (hazard ratio for skin rash grade ≥ 2 vs. grade < 2, 0.44; 95% CI, 0.25 to 0.78; p=0.005).
Conclusion
There were no significant differences in the efficacy between AS and A arms in patients with NA-NSCLC.

Citations

Citations to this article as recorded by  
  • Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity
    Ronald B. Brown
    Journal of Cardiovascular Development and Disease.2024; 11(9): 296.     CrossRef
  • Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma
    Ruilong Wang, Qin Yan, Xiao Liu, Jinfeng Wu
    Biochemical Pharmacology.2024; 223: 116122.     CrossRef
  • Cardiovascular/anti‐inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta‐analysis of randomized trials
    David J. Benjamin, Alyson Haslam, Vinay Prasad
    Cancer Medicine.2024;[Epub]     CrossRef
  • The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea
    Yoo Jung Lee, Nayoon Kang, Junghyun Nam, Eung Gu Lee, Jiwon Ryoo, Soon Seog Kwon, Yong Hyun Kim, Hye Seon Kang, Tsai-Ching Hsu
    PLOS ONE.2024; 19(3): e0299484.     CrossRef
  • DHCR24 in Tumor Diagnosis and Treatment: A Comprehensive Review
    Xin Fu, Zhaosong Wang
    Technology in Cancer Research & Treatment.2024;[Epub]     CrossRef
  • The effects of statins in patients with advanced-stage cancers - a systematic review and meta-analysis
    Qiang Zhou, Zhihua Jiao, Yuxi Liu, Peter N. Devreotes, Zhenyu Zhang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
    Claes R. Andersson, Jiawei Ye, Kristin Blom, Mårten Fryknäs, Rolf Larsson, Peter Nygren
    Anti-Cancer Drugs.2023; 34(1): 92.     CrossRef
  • New insights into the therapeutic potentials of statins in cancer
    Chengyu Liu, Hong Chen, Bicheng Hu, Jiajian Shi, Yuchen Chen, Kun Huang
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Functional significance of cholesterol metabolism in cancer: from threat to treatment
    Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Jialin Li, Hang Xu, Yingjun Zhao, Xianjun Yu, Si Shi
    Experimental & Molecular Medicine.2023; 55(9): 1982.     CrossRef
  • Simvastatin Enhanced Anti-tumor Effects of Bevacizumab against Lung Adenocarcinoma A549 Cells via Abating HIF-1α-Wnt/β-Catenin Signaling Pathway
    Xin Tu, Jian Zhang, Wei Yuan, Xia Wu, Zhi Xu, Cuo Qing
    Anti-Cancer Agents in Medicinal Chemistry.2023; 23(19): 2083.     CrossRef
  • Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs
    Kush K. Patel, Khosrow Kashfi
    Biochemical Pharmacology.2022; 196: 114654.     CrossRef
  • Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
    Yoichi Morofuji, Shinsuke Nakagawa, Kenta Ujifuku, Takashi Fujimoto, Kaishi Otsuka, Masami Niwa, Keisuke Tsutsumi
    Pharmaceuticals.2022; 15(2): 151.     CrossRef
  • Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
    Kamal Eltayeb, Silvia La Monica, Marcello Tiseo, Roberta Alfieri, Claudia Fumarola
    Cells.2022; 11(3): 413.     CrossRef
  • Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role
    Gianmarco Marcianò, Caterina Palleria, Alessandro Casarella, Vincenzo Rania, Emanuele Basile, Luca Catarisano, Cristina Vocca, Luigi Bianco, Corrado Pelaia, Erika Cione, Bruno D’Agostino, Rita Citraro, Giovambattista De Sarro, Luca Gallelli
    Pharmaceuticals.2022; 15(5): 589.     CrossRef
  • The effects of epithelial–mesenchymal transitions in COPD induced by cigarette smoke: an update
    Xiaoshan Su, Weijing Wu, Zhixing Zhu, Xiaoping Lin, Yiming Zeng
    Respiratory Research.2022;[Epub]     CrossRef
  • Scientific Research Directions on the Histopathology and Immunohistochemistry of the Cutaneous Squamous Cell Carcinoma: A Scientometric Study
    Iuliu Gabriel Cocuz, Maria Elena Cocuz, Angela Repanovici, Adrian-Horațiu Sabău, Raluca Niculescu, Andreea-Cătălina Tinca, Vlad Vunvulea, Corina Eugenia Budin, Andreea Raluca Szoke, Maria Cătălina Popelea, Raluca Moraru, Titiana Cornelia Cotoi, Ovidiu Sim
    Medicina.2022; 58(10): 1449.     CrossRef
  • Lipid metabolism and cancer
    Xueli Bian, Rui Liu, Ying Meng, Dongming Xing, Daqian Xu, Zhimin Lu
    Journal of Experimental Medicine.2021;[Epub]     CrossRef
  • Simvastatin-romidepsin combination kills bladder cancer cells synergistically
    Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato
    Translational Oncology.2021; 14(9): 101154.     CrossRef
  • Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
    Woo-Jin Lim, Mingyu Lee, Yerin Oh, Xue-Quan Fang, Sujin Lee, Chang-Hoon Lim, Jooho Park, Ji-Hong Lim
    Cells.2021; 10(9): 2488.     CrossRef
  • ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells
    Jillian Hattaway Luttman, Jacob P. Hoj, Kevin H. Lin, Jiaxing Lin, Jing Jin Gu, Clay Rouse, Amanda G. Nichols, Nancie J. MacIver, Kris C. Wood, Ann Marie Pendergast
    Cell Reports.2021; 37(4): 109880.     CrossRef
  • Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study
    L. Alexandre, A. B. Clark, S. Walton, M. P. Lewis, B. Kumar, E. C. Cheong, H. Warren, S. S. Kadirkamanathan, S. L. Parsons, S. M. Dresner, E. Sims, M. Jones, M. Hammond, M. Flather, Y. K. Loke, A. M. Swart, A. R. Hart
    BJS Open.2020; 4(1): 59.     CrossRef
  • Whether statin use improves the survival of patients with glioblastoma?
    Yonglin Xie, Qin Lu, Cameron Lenahan, Shuxu Yang, Daoyang Zhou, Xuchen Qi
    Medicine.2020; 99(9): e18997.     CrossRef
  • Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
    Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano, Akinori Sato
    Cancer Science.2020; 111(1): 112.     CrossRef
  • Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
    Paolo Gelosa, Laura Castiglioni, Marina Camera, Luigi Sironi
    Biochemical Pharmacology.2020; 177: 113895.     CrossRef
  • Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins
    Sabine Galland, Patricia Martin, Giulia Fregni, Igor Letovanec, Ivan Stamenkovic
    Cancer Letters.2020; 484: 50.     CrossRef
  • Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials
    John P. Thomas, Yoon K. Loke, Leo Alexandre
    European Journal of Clinical Pharmacology.2020; 76(12): 1639.     CrossRef
  • Statins as Anticancer Agents in the Era of Precision Medicine
    Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, Linda Z. Penn
    Clinical Cancer Research.2020; 26(22): 5791.     CrossRef
  • Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
    Sheng Zhou, Huanji Xu, Qiulin Tang, Hongwei Xia, Feng Bi
    Molecular Cancer Therapeutics.2020; 19(1): 135.     CrossRef
  • Repurposed Drugs Trials by Cancer Type
    Joseph C. Murray, Benjamin Levy
    The Cancer Journal.2019; 25(2): 127.     CrossRef
  • Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate
    Saveg Yadav, Shrish Kumar Pandey, Yugal Goel, Mithlesh Kumar Temre, Sukh Mahendra Singh
    Frontiers in Pharmacology.2019;[Epub]     CrossRef
  • Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
    Cheng-Wei Chou, Ching-Heng Lin, Tzu-Hung Hsiao, Chia-Chien Lo, Chih-Ying Hsieh, Cheng-Chung Huang, Yuh-Pyng Sher
    Scientific Reports.2019;[Epub]     CrossRef
  • Drug Repurposing of Metabolic Agents in Malignant Glioma
    Corinna Seliger, Peter Hau
    International Journal of Molecular Sciences.2018; 19(9): 2768.     CrossRef
  • The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials
    Hyun Joo Jang, Hyeong Su Kim, Jung Han Kim, Jin Lee
    Journal of Clinical Medicine.2018; 7(10): 325.     CrossRef
  • Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
    Mohammed A. M. Farooqi, Nikita Malhotra, Som D. Mukherjee, Stephanie Sanger, Sukhbinder K. Dhesy-Thind, Peter Ellis, Darryl P. Leong, Robert M. Lafrenie
    PLOS ONE.2018; 13(12): e0209486.     CrossRef
  • Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells
    Kun Xia, Panpan Zhang, Jian Hu, Huan Hou, Mingdi Xiong, Junping Xiong, Nianlong Yan
    Oncology Letters.2018;[Epub]     CrossRef
  • 11,879 View
  • 343 Download
  • 42 Web of Science
  • 35 Crossref
Close layer
Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls
Ji Soo Park, Eun Ji Nam, Hyung Seok Park, Jung Woo Han, Jung-Yun Lee, Jieun Kim, Tae Il Kim, Seung-Tae Lee
Cancer Res Treat. 2017;49(4):1012-1021.   Published online January 17, 2017
DOI: https://doi.org/10.4143/crt.2016.433
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Comparison of variant frequencies in the general population has become an essential part of the American College of Medical Genetics and Genomics (ACMG) standards and guidelines for interpreting sequence variants. We determined the optimal number of relevant ethnic controls that should be used to accurately calculate the odds ratio (OR) of genetic variants.
Materials and Methods
Using the ACMG guidelines, we reclassified BRCA1 and BRCA2 mutations and variants of unknown significance in 745 Korean patients susceptible to hereditary breast and ovarian cancer compared with 1,314 Korean population controls.
Results
We observed that the ORs were falsely inflated when we analyzed several variants using non-Korean population data. Our simulation indicated that the number of controls needed for the lower limit of a 95% confidence interval to exceed 1.0 varied according to the frequency of the variant in each patient group, with more than 820 controls needed for a variant existing in 1% of cases. Using a sufficient number of relevant population data, we could efficiently classify variants and identified the BRCA1 p.Leu1780Pro mutation as a possible pathogenic founder mutation in Korean patients.
Conclusion
Our study suggests that BRCA1 p.Leu1780Pro is a novel pathogenic mutation found in Korean patients. We also determined the optimal number of relevant ethnic controls needed for accurate variant classification according to the ACMG guidelines.

Citations

Citations to this article as recorded by  
  • Genomic disparity impacts variant classification of cancer susceptibility genes in Turkish breast cancer patients
    Nihat B. Agaoglu, Busra Unal, Connor P. Hayes, McKenzie Walker, Ozden Hatirnaz Ng, Levent Doganay, Nisan D. Can, Huma Q. Rana, Arezou A. Ghazani
    Cancer Medicine.2024;[Epub]     CrossRef
  • Variant reclassification and clinical implications
    Nicola Walsh, Aislinn Cooper, Adrian Dockery, James J O'Byrne
    Journal of Medical Genetics.2024; 61(3): 207.     CrossRef
  • Featuring BRCA1 and BRCA2 germline mutational landscape from Asturias (North Spain)
    Ana S. Pitiot, Pilar Blay, Ander Díaz‐Navarro, Sara Fernández‐Arrojo, Rosa Romero, Ángel Álvarez‐Eguiluz, Marta G. Alvarado, Nieves Álvarez, Paula García‐Teijido, Yolanda Fernández, Isabel Palacio, Xose S. Puente, Milagros Balbín
    Clinical Genetics.2024; 106(4): 525.     CrossRef
  • Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer
    Se-Young Jo, Jeong Dong Lee, Jeongsoo Won, Jiho Park, Taeyong Kweon, Seongyeon Jo, Joohyuk Sohn, Seung-Il Kim, Sangwoo Kim, Hyung Seok Park
    iScience.2024; 27(8): 110469.     CrossRef
  • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
    Jinyong Kim, Kyeonghun Jeong, Hyeji Jun, Kwangsoo Kim, Jeong Mo Bae, Myung Geun Song, Hanbaek Yi, Songyi Park, Go-un Woo, Dae-Won Lee, Tae-Yong Kim, Kyung-Hun Lee, Seock-Ah Im
    Human Genomics.2023;[Epub]     CrossRef
  • Quantitative thresholds for variant enrichment in 13,845 cases: improving pathogenicity classification in genetic hearing loss
    Sihan Liu, Mingjun Zhong, Yu Huang, Qian Zhang, Ting Chen, Xiaofei Xu, Wan Peng, Xiaolu Wang, Xiaoshu Feng, Lu Kang, Yu Lu, Jing Cheng, Fengxiao Bu, Huijun Yuan
    Genome Medicine.2023;[Epub]     CrossRef
  • The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology
    Kelly A. Hirko, Gabrielle Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey I. Cutress, Ellen R. Copson, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im, Yeon Hee Park
    BMC Medicine.2022;[Epub]     CrossRef
  • Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
    Jeong Dong Lee, Won-Ji Ryu, Hyun Ju Han, Tae Yeong Kim, Min Hwan Kim, Joohyuk Sohn
    Cancers.2022; 14(10): 2405.     CrossRef
  • Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
    Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
    Cancer Genetics.2022; 266-267: 19.     CrossRef
  • Hereditary variants of unknown significance in African American women with breast cancer
    J. Tyson McDonald, Luisel J. Ricks-Santi, Alvaro Galli
    PLOS ONE.2022; 17(10): e0273835.     CrossRef
  • Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer
    Qiting Wan, Li Hu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Ye Xu, Yuntao Xie
    Familial Cancer.2021; 20(2): 85.     CrossRef
  • Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
    Joo Heung Kim, Sunggyun Park, Hyung Seok Park, Ji Soo Park, Seung-Tae Lee, Sung-Won Kim, Jong Won Lee, Min Hyuk Lee, Sue K. Park, Woo-Chul Noh, Doo Ho Choi, Wonshik Han, Sung Hoo Jung
    Scientific Reports.2021;[Epub]     CrossRef
  • A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study
    Kyung-Sun Park, Woochang Lee, Moon-Woo Seong, Sun-Young Kong, Kyung-A Lee, Jung-Sook Ha, Eun-Hae Cho, Sung-Hee Han, Inho Park, Jong-Won Kim
    Cancers.2021; 13(9): 2192.     CrossRef
  • Patient perspectives on variant reclassification after cancer susceptibility testing
    Colin M. E. Halverson, Laurie M. Connors, Bronson C. Wessinger, Ellen W. Clayton, Georgia L. Wiesner
    Molecular Genetics & Genomic Medicine.2020;[Epub]     CrossRef
  • Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population
    Dan Li, Yujian Shi, Ang Li, Dandan Cao, Huijun Su, Haiqi Yang, Qihuan Zhi, Yuchen Yang, Zhaoji Lan, Tianliangwen Zhou, Xiaobin You, Guifang Hu
    Breast Cancer.2020; 27(6): 1158.     CrossRef
  • Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant
    Hyung Seok Park, Jai Min Ryu, Ji Soo Park, Seock-Ah Im, So-Youn Jung, Eun-Kyu Kim, Woo-Chan Park, Jun Won Min, Jeeyeon Lee, Ji Young You, Jeong Eon Lee, Sung-Won Kim
    Cancer Research and Treatment.2020; 52(3): 680.     CrossRef
  • Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers
    Hyeong In Ha, Jin-Sun Ryu, Hyoeun Shim, Sun-Young Kong, Myong Cheol Lim
    Journal of Gynecologic Oncology.2020;[Epub]     CrossRef
  • Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea
    Jai Min Ryu, Hee Jun Choi, Isaac Kim, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Doo Ho Choi, Yeon Hee Park, Jong-Won Kim, Jeong-sun Seo, Jung-Hoon Park, Jeong Eon Lee, Sung-Won Kim
    Breast Cancer Research and Treatment.2019; 173(2): 385.     CrossRef
  • Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines
    Min-Kyung So, Tae-Dong Jeong, Woosung Lim, Byung-In Moon, Nam Sun Paik, Seung Cheol Kim, Jungwon Huh
    Breast Cancer.2019; 26(4): 510.     CrossRef
  • Challenges and Considerations in Sequence Variant Interpretation for Mendelian Disorders
    Young-Eun Kim, Chang-Seok Ki, Mi-Ae Jang
    Annals of Laboratory Medicine.2019; 39(5): 421.     CrossRef
  • Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
    Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
    Journal of Ovarian Research.2019;[Epub]     CrossRef
  • Clinical significance of variants of unknown significances in BRCA genes
    Min Chul Choi
    Journal of Gynecologic Oncology.2019;[Epub]     CrossRef
  • Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models
    Hyung Seok Park, Jeong Dong Lee, Jee Ye Kim, Seho Park, Joo Heung Kim, Hyun Ju Han, Yeon A. Choi, Ae Ran Choi, Joo Hyuk Sohn, Seung Il Kim, Harriet Wikman
    PLOS ONE.2019; 14(12): e0225082.     CrossRef
  • Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers
    Ji Soo Park, Seung-Tae Lee, Jung Woo Han, Tae Il Kim, Eun Ji Nam, Hyung Seok Park
    Clinical Breast Cancer.2018; 18(5): 362.     CrossRef
  • Status of BRCA1/2 Genetic Testing Practices in Korea (2014)
    Kyungju Lee, Ja-Hyun Jang, Seung-Tae Lee, Kyong-Ah Yoon, Eun Sook Lee, Jong-Won Kim, Sun-Young Kong
    Laboratory Medicine Online.2018; 8(3): 107.     CrossRef
  • Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing
    Li Dong, Nan Wu, Shaojing Wang, Yanan Cheng, Lei Han, Jing Zhao, Xinxin Long, Kun Mu, Menghui Li, Lijuan Wei, Wanheng Wang, Weijia Zhang, Yandong Cao, Juntian Liu, Jinpu Yu, Xishan Hao
    Human Mutation.2018; 39(10): 1442.     CrossRef
  • Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort
    Jee-Soo Lee, Sohee Oh, Sue Kyung Park, Min-Hyuk Lee, Jong Won Lee, Sung-Won Kim, Byung Ho Son, Dong-Young Noh, Jeong Eon Lee, Hai-Lin Park, Man Jin Kim, Sung Im Cho, Young Kyung Lee, Sung Sup Park, Moon-Woo Seong
    Journal of Medical Genetics.2018; 55(12): 794.     CrossRef
  • Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from ‘unknown significance’ to ‘Likely pathogenic’ based on clinical evidence in Korea
    Jai Min Ryu, Goeun Kang, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Soo Youn Bae, Sungmin Park, Hyun-June Paik, Jong-Won Kim, Sung-Shin Park, Jeong Eon Lee, Sung-Won Kim
    The Breast.2017; 33: 109.     CrossRef
  • 14,414 View
  • 645 Download
  • 26 Web of Science
  • 28 Crossref
Close layer
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
Sang Myung Woo, Min Kyeong Kim, Jungnam Joo, Kyong-Ah Yoon, Boram Park, Sang-Jae Park, Sung-Sik Han, Ju Hee Lee, Eun Kyung Hong, Yun-Hee Kim, Hae Moon, Sun-Young Kong, Tae Hyun Kim, Woo Jin Lee
Cancer Res Treat. 2017;49(4):1022-1032.   Published online January 19, 2017
DOI: https://doi.org/10.4143/crt.2016.495
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study assessed the feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost–intensity modulated radiotherapy (SIB-IMRT) with concurrent gemcitabine in patients with locally advanced unresectable pancreatic cancer.
Materials and Methods
In this trial, patients received induction chemotherapy consisting of gemcitabine (1,000 mg/m2) and cisplatin (25 mg/m2) on days 1, 8, and 15 of each treatment cycle. Patients were subsequently treated with gemcitabine (300 mg/m2/wk) during SIB-IMRT. The patients received total doses of 55 and 44 Gy in 22 fractions to planning target volume 1 and 2, respectively. As an ancillary study, digital polymerase chain reaction was performed to screen for the seven most common mutations in codons 12 and 13 of the KRAS oncogene of circulating cell free DNA (cfDNA).
Results
Forty-four patients were enrolled between 2012 and 2015. Of these, 33 (75%) completed the treatment. The most common toxicities during induction chemotherapy were grades 3 and 4 neutropenia (18.2%), grade 3 nausea (6.8%) and vomiting (6.8%). The most common toxicities during SIB-IMRT were grade 3 neutropenia (24.2%) and grade 3 anemia (12.1%). Ten patients (23%) underwent a curative resection after therapy. Median overall survival was significantly longer in patients who underwent curative resection (16.8 months vs. 11 months, p < 0.01). The median cfDNA concentration was significantly lower after treatment (108.5 ng/mL vs. 18.4 ng/mL, p < 0.001).
Conclusion
Induction chemotherapy with gemcitabine and cisplatin followed by concurrent SIB-IMRT was well tolerated and active.

Citations

Citations to this article as recorded by  
  • Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
    Krishan R. Jethwa, Ed Kim, Jordan Berlin, Christopher J. Anker, Leila Tchelebi, Gerard Abood, Christopher L. Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo
    American Journal of Clinical Oncology.2024; 47(4): 185.     CrossRef
  • Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer
    Y. Li, J. Wu, Y. Feng, D. Wang, H. Tao, J. Wen, F. Jiang, P. Qian, Y. Liu
    Cancer/Radiothérapie.2024; 28(3): 242.     CrossRef
  • Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?
    Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solène Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet
    Digestive and Liver Disease.2022; 54(10): 1428.     CrossRef
  • Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
    Marisol Huerta, Susana Roselló, Luis Sabater, Ana Ferrer, Noelia Tarazona, Desamparados Roda, Valentina Gambardella, Clara Alfaro-Cervelló, Marina Garcés-Albir, Andrés Cervantes, Maider Ibarrola-Villava
    Cancers.2021; 13(5): 994.     CrossRef
  • Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
    Irina Palacín-Aliana, Noemí García-Romero, Adrià Asensi-Puig, Josefa Carrión-Navarro, Víctor González-Rumayor, Ángel Ayuso-Sacido
    Biomedicines.2021; 9(8): 906.     CrossRef
  • A review on the efficacy and safety of iodine-125 seed implantation in unresectable pancreatic cancers
    Sheng-Nan Jia, Fu-Xing Wen, Ting-Ting Gong, Xin Li, Hui-Jie Wang, Ya-Min Sun, Ze-Cheng Yang
    International Journal of Radiation Biology.2020; 96(3): 383.     CrossRef
  • Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer
    Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Eun Sang Oh, Sang Hee Youn, Hye Young Jang, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
    Kyong-Ah Yoon, Sang Myung Woo, Yun-Hee Kim, Sun-Young Kong, Min Kyoung Lee, Sung-Sik Han, Tae Hyun Kim, Woo Jin Lee, Sang-Jae Park
    Gut and Liver.2019; 13(6): 683.     CrossRef
  • Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma
    Sangjoon Park, Eun Jung Lee, Chai Hong Rim, Jinsil Seong
    Yonsei Medical Journal.2018; 59(4): 470.     CrossRef
  • Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer
    Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Hyunjung Kim, Eun Sang Oh, Ju Hee Lee, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
    Technology in Cancer Research & Treatment.2018;[Epub]     CrossRef
  • 9,790 View
  • 254 Download
  • 11 Web of Science
  • 10 Crossref
Close layer
Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
Yoojoo Lim, Jee Min Lim, Won Jae Jeong, Kyung-Hun Lee, Bhumsuk Keam, Tae-Yong Kim, Tae Min Kim, Sae-Won Han, Do Youn Oh, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Seock-Ah Im
Cancer Res Treat. 2017;49(4):1033-1043.   Published online April 7, 2017
DOI: https://doi.org/10.4143/crt.2016.413
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to assess current levels of awareness of clinical trials (CTs), perceptions regarding their benefits and willingness to participate to CTs among Korean cancer patients.
Materials and Methods
From December 2012 to August 2015, we distributed questionnaires to cancer patients receiving systemic anti-cancer therapy at Seoul National University Hospital, Seoul, Korea.
Results
A total of 397 out of 520 requested patients (76.3%) responded to the survey. Among the 397 patients, 62.5% were female and the median age was 52 years. Overall, 97.4% (387/397) answered that they have at least heard of CTs. When asked about their level of awareness, 23.8% (92/387) answered that they could more than roughly explain about CTs. The average visual analogue scale score of CT benefit in all patients was 6.43 (standard deviation, 2.20). Patients who were only familiar with the term without detailed knowledge of the contents had the least expectation of benefit from CTs (p=0.015). When asked about their willingness to participate in CTs, 56.7% (225/397) answered positively. Patients with higher levels of awareness of CTs showed higher willingness to participate (p < 0.001). Heavily treated patients and patients with previous experience regarding CTs also showed a higher willingness to participate (p < 0.001). The perceived benefit of CTs was higher in the group willing to participate (p=0.026).
Conclusion
The patient’s level of awareness regarding CTs was positively related to the positive perception and willingness to participate. Although the general awareness of CTs was high, a relatively large proportion of patients did not have accurate knowledge; therefore, proper and accurate patient education is necessary.

Citations

Citations to this article as recorded by  
  • Depression and anxiety among hemophilia patients enrolled in clinical trials: a multi-center cohort study
    Zhen Peng, Xiaoyu Zhu, Chongwei Wang, Mingfeng Zhou, Xiaoling Xu, Yin Chen
    Annals of Hematology.2023; 102(7): 1927.     CrossRef
  • Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events
    Zhen Peng, Chongwei Wang, Yubei Sun, Yan Ma, Jumei Wang, Fei Xu, Xiaoling Xu, Yin Chen
    Cancer Medicine.2023; 12(19): 20015.     CrossRef
  • Acceptance Factors and Psychological Investigation of Clinical Trials in Cancer Patients
    Jiangjie Sun, Jingyi Fang, Chenchen Zhang, Nannan Jia, Weiming Zhao, Jinjian Gao, Yingying Huang, Jiqing Hao, Liping Zhang, Carmen M Galvez-Sánchez
    Behavioural Neurology.2023; 2023: 1.     CrossRef
  • Understanding and attitudes of the Jordanian public about clinical research ethics
    Mera A Ababneh, Sayer I Al-Azzam, Karem Alzoubi, Abeer Rababa’h, Saddam Al Demour
    Research Ethics.2021; 17(2): 228.     CrossRef
  • A patient-focused, theory-guided approach to survey design identified barriers to and drivers of clinical trial participation
    Jamie C. Brehaut, Kelly Carroll, Justin Presseau, Dawn P. Richards, Jenn Gordon, Angèle Bénard, Natasha Hudek, Ian D. Graham, Dean A. Fergusson, Susan Marlin
    Journal of Clinical Epidemiology.2021; 132: 106.     CrossRef
  • Awareness of breast cancer patients in Poland about clinical trials as available treatment options
    Mikołaj Bartoszkiewicz, Joanna Kufel-Grabowska, Maria Litwiniuk
    Breast Disease.2021; 40(1): 33.     CrossRef
  • Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them
    Jamie C. Brehaut, Kelly Carroll, Jenn Gordon, Justin Presseau, Dawn P. Richards, Dean A. Fergusson, Ian D. Graham, Susan Marlin
    Current Oncology.2021; 28(3): 2014.     CrossRef
  • Regional Differences in Access to Clinical Trials for Cancer in Korea
    Woorim Kim, Seongkyeong Jang, Yoon Jung Chang
    Quality Improvement in Health Care.2021; 27(1): 20.     CrossRef
  • How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers
    Ji Hyun Park, Ji Sung Lee, HaYeong Koo, Jeong Eun Kim, Jin-Hee Ahn, Min-Hee Ryu, Sook-ryun Park, Shin-kyo Yoon, Jae Cheol Lee, Yong-Sang Hong, Sun Young Kim, Kyo-Pyo Kim, Chang-Hoon Yoo, Jung Yong Hong, Jae Lyun Lee, Kyung Hae Jung, Baek-Yeol Rhyoo, Tae W
    Journal of Cancer Education.2020; 35(3): 545.     CrossRef
  • Colorectal cancer survivors’ willingness to participate in a hypothetical clinical trial of Korean medicine: A cross-sectional study
    Yown Hwangbo, Gyung Mo Son, Kyung Hee Kim, Myeong Sook Kwon, Kun Hyung Kim
    European Journal of Integrative Medicine.2020; 33: 101033.     CrossRef
  • Perception and Satisfaction of Anticancer Drug Clinical Trials in Cancer Patients
    Ju Kyung Jeon, Jeong Hye Kim
    Asian Oncology Nursing.2019; 19(1): 18.     CrossRef
  • Challenges in informed consent decision-making in Korean clinical research: A participant perspective
    Im-Soon Choi, Eun Young Choi, Iyn-Hyang Lee, Dermot Cox
    PLOS ONE.2019; 14(5): e0216889.     CrossRef
  • Clinical Trials: What, Where, When?
    Olga S. Kobyakova, Ivan A. Deev, Evgeny S. Kulikov, Roman I. Shtykh, Igor D. Pimenov, Olga I. Zvonareva, Igor V. Mareev
    Annals of the Russian academy of medical sciences.2018; 73(5): 314.     CrossRef
  • 8,270 View
  • 178 Download
  • 11 Web of Science
  • 13 Crossref
Close layer
Effects of Soy Product Intake and Interleukin Genetic Polymorphisms on Early Gastric Cancer Risk in Korea: A Case-Control Study
Sarah Yang, Yoon Park, Jeonghee Lee, Il Ju Choi, Young Woo Kim, Keun Won Ryu, Joohon Sung, Jeongseon Kim
Cancer Res Treat. 2017;49(4):1044-1056.   Published online January 19, 2017
DOI: https://doi.org/10.4143/crt.2016.515
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The current study investigated whether the combined effects of soy intake and genetic polymorphisms of interleukin (IL) genes modify gastric cancer risk.
Materials and Methods
A total of 377 cases and 754 controls of Korean origin were included in the analysis. Soy consumption was assessed using a semi-quantitative food frequency questionnaire. Seven variants of IL10 (rs1800871), IL2 (rs2069763 and rs2069762), IL13 (rs6596090 and rs20541), and IL4R(rs7205663 and rs1805010) were genetically analyzed. To analyze the combined effect of soy intake and genetic polymorphisms, a low-intake group and high-intake group of each type of soy were categorized based on the intake level of the control group. Interactions between soy products and these genetic variants were analyzed by a likelihood ratio test, in which a multiplicative interaction term was added to the logistic regression model.
Results
A higher intake of nonfermented soy products was associated with a reduced cancer risk (odds ratio [OR], 0.62; 95% confidence interval [CI], 0.43 to 0.90), and the reduced risk was only apparent in males (OR, 0.44; 95% CI, 0.27 to 0.71). None of the IL genetic polymorphisms examined were independently associated with gastric cancer risk. Individuals with a minor allele of IL2 rs2069762 and a higher intake of nonfermented soy food had a decreased risk of gastric cancer (OR, 0.46; 95% CI, 0.31 to 0.68) compared to those with a lower intake (pinteraction=0.039).
Conclusion
Based on the genetic characteristics of the studied individuals, the interaction between IL2 rs2069762 and nonfermented soy intake may modify the risk of gastric cancer.

Citations

Citations to this article as recorded by  
  • Polyphenol intake and gastric cancer: A case-control study in the Brazilian Amazon region
    Marcela de Araújo Fagundes, Renata Alves Carnauba, Gisele Aparecida Fernandes, Paulo Pimentel de Assumpção, Maria Paula Curado
    Cancer Epidemiology.2024; 88: 102518.     CrossRef
  • Oral Microbiota as a Diagnostic Biomarker of Digestive Cancer: A Systematic Review
    SK Aziz Ikbal, Surendra Kumar Yadav, Roopanshi Mehrotra, Tasneem Fatima, Anjusha Sharda, Srashti Gupta
    The Journal of Contemporary Dental Practice.2024; 24(11): 902.     CrossRef
  • The pertinence of gastric cancer and interleukin 10–819 single nucleotide polymorphisms: a meta-analysis and systematic review
    Qianqian Mao, Yanwen Liu, Xi Chen, Cheng Jiang Liu
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Soy Product Consumption and the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies
    Chenting Wang, Keqing Ding, Xuanzhen Xie, Jinyue Zhou, Pengju Liu, Shuang Wang, Ting Fang, Guozhang Xu, Chunlan Tang, Hang Hong
    Nutrients.2024; 16(7): 986.     CrossRef
  • Interaction between dietary potassium intake and TNF-α rs1800629 genetic polymorphism in gastric cancer risk: a case–control study conducted in Korea
    Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    British Journal of Nutrition.2023; 130(5): 887.     CrossRef
  • Association between soy products, fruits, vegetables, and dairy products and gastric cancer risk in Helicobacter pylori-infected subjects: a case-control study in Korea
    Jung Hyun Kwak, Chang Soo Eun, Dong Soo Han, Yong Sung Kim, Kyu Sang Song, Bo Youl Choi, Hyun Ja Kim
    Nutrition Research and Practice.2023; 17(1): 122.     CrossRef
  • Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies
    Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim
    Epidemiology and Health.2023; 45: e2023102.     CrossRef
  • The association of dietary fibre intake and the IL13 rs20541 polymorphism with the risk of gastric cancer: a case-control study in Korea
    Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    European Journal of Clinical Nutrition.2022; 76(7): 1031.     CrossRef
  • Dietary Polyphenol Intake and Gastric Cancer: A Systematic Review and Meta-Analysis
    Marcela de Araújo Fagundes, Alex Richard Costa Silva, Gisele Aparecida Fernandes, Maria Paula Curado
    Cancers.2022; 14(23): 5878.     CrossRef
  • Sex-dependent associations between MAP3K1 gene polymorphisms and soy products with the gastric cancer risk in Korea: a case-control study
    Jung Hyun Kwak, Chang Soo Eun, Dong Soo Han, Yong Sung Kim, Kyu Sang Song, Bo Youl Choi, Hyun Ja Kim
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Dietary patterns and gastric cancer risk in a Korean population: a case–control study
    Ji Hyun Kim, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    European Journal of Nutrition.2021; 60(1): 389.     CrossRef
  • Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer
    Xujun Song, Benno Traub, Jingwei Shi, Marko Kornmann
    International Journal of Molecular Sciences.2021; 22(2): 727.     CrossRef
  • The association between soy‐based food and soy isoflavone intake and the risk of gastric cancer: a systematic review and meta‐analysis
    Yameng Wang, Jiaping Guo, Fei Yu, Yongmei Tian, Yongjun Wu, Lingling Cui, Li‐e Liu
    Journal of the Science of Food and Agriculture.2021; 101(13): 5314.     CrossRef
  • The Associations of Dietary Iron Intake and the Transferrin Receptor (TFRC) rs9846149 Polymorphism with the Risk of Gastric Cancer: A Case–Control Study Conducted in Korea
    Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    Nutrients.2021; 13(8): 2600.     CrossRef
  • Identification of Dietary Pattern Networks Associated with Gastric Cancer Using Gaussian Graphical Models: A Case-Control Study
    Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    Cancers.2020; 12(4): 1044.     CrossRef
  • Genome‐wide profiling of normal gastric mucosa identifies Helicobacter pylori‐ and cancer‐associated DNA methylome changes
    Hae Dong Woo, Nora Fernandez‐Jimenez, Akram Ghantous, Davide Degli Esposti, Cyrille Cuenin, Vincent Cahais, Il Ju Choi, Young‐Il Kim, Jeongseon Kim, Zdenko Herceg
    International Journal of Cancer.2018; 143(3): 597.     CrossRef
  • The association between dietary isoflavones intake and gastric cancer risk: a meta-analysis of epidemiological studies
    Jie You, Yafei Sun, Yacong Bo, Yiwei Zhu, Dandan Duan, Han Cui, Quanjun Lu
    BMC Public Health.2018;[Epub]     CrossRef
  • 9,538 View
  • 280 Download
  • 17 Web of Science
  • 17 Crossref
Close layer
Gonadal and Sexual Dysfunction in Childhood Cancer Survivors
Ju Young Yoon, Hyeon Jin Park, Hee Young Ju, Jong Hyung Yoon, Jin Soo Chung, Sang Hyun Hwang, Dong Ock Lee, Hye Young Shim, Byung-Kiu Park
Cancer Res Treat. 2017;49(4):1057-1064.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.197
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Few studies have addressed gonadal and sexual dysfunctions in childhood cancer survivors. We evaluated the prevalence rates and risk factors for gonadal failure among adolescent/young adult childhood cancer survivors and their sexual function.
Materials and Methods
Subjects were childhood cancer survivors aged 15-29 years who had completed therapy more than 2 years ago. Demographic and medical characteristics were obtained from the patients’ medical records. In addition, hormonal evaluation and semen analysis were performed and sexual function was evaluated via questionnaire.
Results
The study included 105 survivors (57 males, 48 females), of which 61 were adults (age > 19 years) and 44 were adolescents. In both males and females, the proportion of survivors with low sex hormone levels did not differ among age groups or follow-up period. Thirteen female subjects (27.1%) needed sex hormone replacement, while five males subjects (8.8%) were suspected of having hypogonadism, but none were receiving sex hormone replacement. Of 27 semen samples, 14 showed azospermia or oligospermia. The proportion of normospermia was lower in the high cyclophosphamide equivalent dose (CED) group (CED ≥ 8,000 mg/m2) than the low CED group (27.3% vs. 62.5%, p=0.047). Among adults, none were married and only 10 men (35.7%) and eight women (34.3%) were in a romantic relationship. Though a significant proportion (12.0% of males and 5.3% of females) of adolescent survivors had experienced sexual activity, 13.6% had not experienced sex education.
Conclusion
The childhood cancer survivors in this study showed a high prevalence of gonadal/sexual dysfunction; accordingly, proper strategies are needed to manage these complications.

Citations

Citations to this article as recorded by  
  • Sexual and reproductive complications and concerns of survivors of childhood, adolescent and adult cancer
    Brigitte Gerstl, Christina Signorelli, Claire E. Wakefield, Rebecca Deans, Tejnei Vaishnav, Karen Johnston, Kristen Neville, Richard J. Cohn, Antoinette Anazodo
    Journal of Cancer Survivorship.2024; 18(4): 1201.     CrossRef
  • α‐Ketoglutarate Improves Ovarian Reserve Function in Primary Ovarian Insufficiency by Inhibiting NLRP3‐Mediated Pyroptosis of Granulosa Cells
    Ke Liu, Yafei Wu, Wenqin Yang, Tianlong Li, Zhongxu Wang, Shu Xiao, Zhenghua Peng, Meng Li, Wenhao Xiong, Meixiang Li, Xi Chen, Shun Zhang, Xiaocan Lei
    Molecular Nutrition & Food Research.2024;[Epub]     CrossRef
  • Huangqi‐Guizhi‐Wuwutang protects against oligospermia in mice by promoting the proliferation of spermatogenic stem cells: A comprehensive study using HPLC‐Q‐TOF/MS and experimental pharmacology
    Yuan Zhao, Jinru Wu, Xiangbin Li, Lin Zheng, Qiugu Chen, Shangbin Zhang, Jianping Chen
    Biomedical Chromatography.2024;[Epub]     CrossRef
  • Sexual Dysfunction Among Adolescent and Young Adult Men Diagnosed with Cancer
    Quinn Carroll Rainer, Justin Michael Dubin, Navin Chakravarthy Balaji, Victoria Troesch, William Terry, Varun Monga, Lindsey Clifford, Jamie Shoag, Aubrey Greer, Sirpi Nackeeran, Alejandro Aaron Rodriguez, Premal Patel, Lisa Paz, Bruce Richard Kava, Warre
    Journal of Adolescent and Young Adult Oncology.2023; 12(1): 93.     CrossRef
  • Reproductive Care of Childhood and Adolescent Cancer Survivors: A 12-Year Evaluation
    Antoinette Catherine Anazodo, Sumin Choi, Christina Signorelli, Sarah Ellis, Karen Johnston, Claire E. Wakefield, Rebecca Deans, Kristen A. Neville, Richard J. Cohn
    Journal of Adolescent and Young Adult Oncology.2021; 10(2): 131.     CrossRef
  • Fatherhood Following Treatment for Testicular Cancer: A Systematic Review and Meta-Analyses
    Brigitte Gerstl, Michael J. Bertoldo, Elizabeth Sullivan, Xanthie Volckmar, Aidan Kerr, Handan Wand, Angela Ives, Olayan Albalawi, Antoinette Anazodo
    Journal of Adolescent and Young Adult Oncology.2020; 9(3): 341.     CrossRef
  • Male and Female Sexual Dysfunction in Pediatric Cancer Survivors
    Daniel R. Greenberg, Yash S. Khandwala, Hriday P. Bhambhvani, Pamela J. Simon, Michael L. Eisenberg
    The Journal of Sexual Medicine.2020; 17(9): 1715.     CrossRef
  • Novel therapies for childhood cancer and impact on puberty
    Christina Wei, Michael Stevens, Elizabeth Crowne
    Current Opinion in Endocrine and Metabolic Research.2020; 14: 112.     CrossRef
  • Psychosexual Functioning of Female Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort Study
    Kari L. Bjornard, Carrie R. Howell, James L. Klosky, Wassim Chemaitilly, Deo Kumar Srivastava, Tara M. Brinkman, Daniel M. Green, Victoria W. Willard, Lisa M. Jacola, Matthew J. Krasin, Melissa M. Hudson, Leslie L. Robison, Kirsten K. Ness
    The Journal of Sexual Medicine.2020; 17(10): 1981.     CrossRef
  • Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention
    Lei Chen, Guang-rui Shi, Dan-dan Huang, Yang Li, Chen-chao Ma, Min Shi, Bin-xiao Su, Guang-jiang Shi
    Biomedicine & Pharmacotherapy.2019; 112: 108585.     CrossRef
  • Survival from cancer in young people: An overview of late effects focusing on reproductive health
    Hannah L. Newton, Amanda J. Friend, Richard Feltbower, Catherine J. Hayden, Helen M. Picton, Adam W. Glaser
    Acta Obstetricia et Gynecologica Scandinavica.2019; 98(5): 573.     CrossRef
  • Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review
    Long Hin Jonathan Poon, Chun-Pong Yu, Liwen Peng, Celeste Lom-Ying Ewig, Hui Zhang, Chi-Kong Li, Yin Ting Cheung
    Journal of Cancer Survivorship.2019; 13(3): 374.     CrossRef
  • The impact of childhood cancer and its treatment on puberty and subsequent hypothalamic pituitary and gonadal function, in both boys and girls
    Christina Wei, Elizabeth Crowne
    Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(3): 101291.     CrossRef
  • Urological Survivorship Issues Among Adolescent Boys and Young Men Who Are Cancer Survivors
    Troy Sukhu, Sherry Ross, R. Matthew Coward
    Sexual Medicine Reviews.2018; 6(3): 396.     CrossRef
  • 11,204 View
  • 300 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients
Mi-Sook Lee, Eun Ah Jung, Sung Bin An, Yu Jin Kim, Doo-Yi Oh, Ji-Young Song, Sang-Won Um, Joungho Han, Yoon-La Choi
Cancer Res Treat. 2017;49(4):1065-1076.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.347
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The discoidin domain-containing receptor tyrosine kinase 2 (DDR2) is known to contain mutations in a small subset of patients with squamous cell carcinomas (SCC) of the lung. Studying the DDR2 mutations in patients with SCC of the lung would advance our understanding and guide the development of therapeutic strategies against lung cancer.
Materials and Methods
We selected 100 samples through a preliminary genetic screen, including specimens from biopsies and surgical resection, and confirmed SCC by histologic examination. DDR2 mutations on exons 6, 15, 16, and 18 were analyzed by Sanger sequencing of formalin-fixed, paraffin-embedded tissue samples. The functional effects of novel DDR2 mutants were confirmed by in vitro assays.
Results
We identified novel somatic mutations of DDR2 in two of the 100 SCC samples studied. One mutation was c.1745T>A (p.V582E) and the other was c.1784T>C (p.L595P), and both were on exon 15. Both patients were smokers and EGFR/KRAS/ALK-triple negative. The expression of the mutant DDR2 induced activation of DDR2 by the collagen ligand and caused enhanced cell growth and tumor progression. Moreover, dasatinib, a DDR2 inhibitor, showed potential efficacy against DDR2 L595P mutant–bearing cells.
Conclusion
Our results suggest that a mutation in DDR2 occurs naturally with a frequency of about 2% in Korean lung SCC patients. In addition, we showed that each of the novel DDR2 mutations were located in a kinase domain and induced an increase in cell proliferation rate.

Citations

Citations to this article as recorded by  
  • Potentially functional variants of PARK7 and DDR2 in ferroptosis‐related genes predict survival of non‐small cell lung cancer patients
    Huilin Wang, Hongliang Liu, Xiaozhun Tang, Guojun Lu, Sheng Luo, Mulong Du, David C. Christiani, Qingyi Wei
    International Journal of Cancer.2024;[Epub]     CrossRef
  • Discoidin Domain Receptor 2: A New Target in Cancer
    Xiaoxiao Xu, Tong Yu, Zhenxing Wang
    Oncology Research and Treatment.2022; 45(4): 205.     CrossRef
  • Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing
    Sungbin An, Hyun Hee Koh, Eun Sol Chang, Juyoung Choi, Ji-Young Song, Mi-Sook Lee, Yoon-La Choi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Squamous cell lung cancer: Current landscape and future therapeutic options
    Sally C.M. Lau, Yuanwang Pan, Vamsidhar Velcheti, Kwok Kin Wong
    Cancer Cell.2022; 40(11): 1279.     CrossRef
  • Complex roles of discoidin domain receptor tyrosine kinases in cancer
    V. Mehta, H. Chander, A. Munshi
    Clinical and Translational Oncology.2021; 23(8): 1497.     CrossRef
  • The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development
    Sandra Majo, Patrick Auguste
    Cancers.2021; 13(7): 1725.     CrossRef
  • Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing
    Charles Ricordel, Alexandra Lespagnol, Francisco Llamas-Gutierrez, Marie de Tayrac, Mallorie Kerjouan, Alice Fievet, Houda Hamdi-Rozé, Amyrat Aliouat, Benoit Desrues, Jean Mosser, Hervé Léna
    Clinical Lung Cancer.2018; 19(2): 163.     CrossRef
  • Extracellular matrix functions in lung cancer
    Martin Götte, Ilona Kovalszky
    Matrix Biology.2018; 73: 105.     CrossRef
  • Subjecting appropriate lung adenocarcinoma samples to next‐generation sequencing‐based molecular testing: challenges and possible solutions
    Weihua Li, Tian Qiu, Yun Ling, Shugeng Gao, Jianming Ying
    Molecular Oncology.2018; 12(5): 677.     CrossRef
  • Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
    Ugo Testa, Germana Castelli, Elvira Pelosi
    Cancers.2018; 10(8): 248.     CrossRef
  • Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
    Zahra Fathi, Seyed Ali Javad Mousavi, Raheleh Roudi, Farideh Ghazi, Sumitra Deb
    PLOS ONE.2018; 13(7): e0200633.     CrossRef
  • 10,142 View
  • 249 Download
  • 14 Web of Science
  • 11 Crossref
Close layer
Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer
Si-Hyun Lee, Hwang-Phill Kim, Jun-Kyu Kang, Sang-Hyun Song, Sae-Won Han, Tae-You Kim
Cancer Res Treat. 2017;49(4):1077-1087.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.301
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
RNA editing generates protein diversity by altering RNA sequences in coding regions without changing the overall DNA sequence. Adenosine-to-inosine (A-to-I) RNA editing events have recently been reported in some types of cancer, but they are rare in human colorectal cancer (CRC). Therefore, this study was conducted to identify diverse RNA editing in CRC.
Materials and Methods
We compared transcriptome data of 39 CRC samples and paired adjacent tissues from The Cancer Genome Atlas database to identify RNA editing patterns in CRC, focusing on canonical A-to-I RNA edits in coding sequence regions. We investigated nonsynonymous RNA editing patterns by comparing tumor and normal tissue transcriptome data.
Results
The number of RNA edits varied from 12 to 42 per sample. We also observed that hypoand hyper-RNA editing patterns were distinguishable within the samples. We found 10 recurrent nonsynonymous RNA editing candidates in nine genes (PDLIM, NEIL1, SRP9, GLI1, APMAP, IGFBP7, ZNF358, COPA, and ZNF587B) and validated some by Sanger sequencing and the inosine chemical erasing assay. We further showed that editing at these positions was performed by the adenosine deaminase acting on RNA 1 enzyme. Most of these genes are hypoedited in CRC, but editing of GLI1 was increased in cancer tissues compared with normal tissues.
Conclusion
Our results show that nonsynonymous RNA editing patterns can be used to identify CRC patients and could serve as novel biomarkers for CRC.

Citations

Citations to this article as recorded by  
  • ADAR-mediated RNA editing regulates PVR immune checkpoint in colorectal cancer
    Cheng-Jia Qian, Yu-Shan He, Tao Guo, Ji Tao, Zhi-Yuan Wei, Jia-Li Zhang, Chuanqing Bao, Jian-Huan Chen
    Biochemical and Biophysical Research Communications.2024; 695: 149373.     CrossRef
  • Screening and identification of serum exosomal protein ZNF587B in liquid biopsy for ovarian cancer diagnosis
    Hu Li
    American Journal of Cancer Research.2024; 14(4): 1904.     CrossRef
  • COPA A-to-I RNA editing hijacks endoplasmic reticulum stress to promote metastasis in colorectal cancer
    Shu-yang Wang, Ling-jie Zhang, Guo-jun Chen, Qi-qi Ni, Yuan Huang, Dan Zhang, Fang-yi Han, Wen-feng He, Li-ling He, Yan-qing Ding, Hong-li Jiao, Ya-ping Ye
    Cancer Letters.2023; 553: 215995.     CrossRef
  • The Interplay between RNA Editing Regulator ADAR1 and Immune Environment in Colorectal Cancer
    Guo-Liang Zheng, Guo-Jun Zhang, Yan Zhao, Zhi-Chao Zheng, Xueliang Wu
    Journal of Oncology.2023; 2023: 1.     CrossRef
  • Signal Recognition Particle in Human Diseases
    Morgana K. Kellogg, Elena B. Tikhonova, Andrey L. Karamyshev
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor
    Dipak Kumar Sahoo, Dana C. Borcherding, Lawrance Chandra, Albert E. Jergens, Todd Atherly, Agnes Bourgois-Mochel, N. Matthew Ellinwood, Elizabeth Snella, Andrew J. Severin, Martin Martin, Karin Allenspach, Jonathan P. Mochel
    Cancers.2022; 14(14): 3525.     CrossRef
  • Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment
    Hiromichi Sato, Kazuki Sasaki, Tomoaki Hara, Shogo Kobayashi, Yuichiro Doki, Hidetoshi Eguchi, Taroh Satoh, Hideshi Ishii
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • A signal recognition particle-related joint model of LASSO regression, SVM-RFE and artificial neural network for the diagnosis of systemic sclerosis-associated pulmonary hypertension
    Jingxi Xu, Chaoyang Liang, Jiangtao Li
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Establishment and validation of an RNA binding protein-associated prognostic model for ovarian cancer
    Chaofan He, Fuxin Huang, Kejia Zhang, Jun Wei, Ke Hu, Meng Liang
    Journal of Ovarian Research.2021;[Epub]     CrossRef
  • The Emerging Impact of RNA Editing in Tumor Growth and Metastasis
    Mehrdad Nasrollahzadehsabet, Javad Behroozi
    Annals of Military and Health Sciences Research.2021;[Epub]     CrossRef
  • Noncanonical Functions and Cellular Dynamics of the Mammalian Signal Recognition Particle Components
    Camilla Faoro, Sandro F. Ataide
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD82 Cell Line
    Shuo Wang, Jiang Chen, Hongyu Li, Xingshun Qi, Xu Liu, Xiaozhong Guo
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • Conservation of A-to-I RNA editing in bowhead whale and pig
    Knud Larsen, Mads Peter Heide-Jørgensen, Alexander F. Palazzo
    PLOS ONE.2021; 16(12): e0260081.     CrossRef
  • Quantifying RNA Editing in Deep Transcriptome Datasets
    Claudio Lo Giudice, Domenico Alessandro Silvestris, Shalom Hillel Roth, Eli Eisenberg, Graziano Pesole, Angela Gallo, Ernesto Picardi
    Frontiers in Genetics.2020;[Epub]     CrossRef
  • The Novel Zinc Finger Protein 587B Gene, ZNF587B, Regulates Cell Proliferation and Metastasis in Ovarian Cancer Cells in vivo and in vitro


    Yujie Liu, Qianying Ouyang, Zeen Sun, Jieqiong Tan, Weihua Huang, Jie Liu, Zhaoqian Liu, Honghao Zhou, Feiyue Zeng, Yingzi Liu
    Cancer Management and Research.2020; Volume 12: 5119.     CrossRef
  • Non-Coding RNA Editing in Cancer Pathogenesis
    Giulia Romano, Michela Saviana, Patricia Le, Howard Li, Lavender Micalo, Giovanni Nigita, Mario Acunzo, Patrick Nana-Sinkam
    Cancers.2020; 12(7): 1845.     CrossRef
  • Automated Isoform Diversity Detector (AIDD): a pipeline for investigating transcriptome diversity of RNA-seq data
    Noel-Marie Plonski, Emily Johnson, Madeline Frederick, Heather Mercer, Gail Fraizer, Richard Meindl, Gemma Casadesus, Helen Piontkivska
    BMC Bioinformatics.2020;[Epub]     CrossRef
  • RNA editing alterations define manifestation of prion diseases
    Eirini Kanata, Franc Llorens, Dimitra Dafou, Athanasios Dimitriadis, Katrin Thüne, Konstantinos Xanthopoulos, Nikolaos Bekas, Juan Carlos Espinosa, Matthias Schmitz, Alba Marín-Moreno, Vincenzo Capece, Orr Shormoni, Olivier Andréoletti, Stefan Bonn, Juan
    Proceedings of the National Academy of Sciences.2019; 116(39): 19727.     CrossRef
  • Epigenetic and epitranscriptomic changes in colorectal cancer: diagnostic, prognostic, and treatment implications
    Elisa Porcellini, Noemi Laprovitera, Mattia Riefolo, Matteo Ravaioli, Ingrid Garajova, Manuela Ferracin
    Cancer Letters.2018;[Epub]     CrossRef
  • Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis
    Phaik Ju Teoh, Omer An, Tae-Hoon Chung, Jing Yuan Chooi, Sabrina H. M. Toh, Shuangyi Fan, Wilson Wang, Bryan T. H. Koh, Melissa J. Fullwood, Melissa G. Ooi, Sanjay de Mel, Cinnie Y. Soekojo, Leilei Chen, Siok Bian Ng, Henry Yang, Wee Joo Chng
    Blood.2018; 132(12): 1304.     CrossRef
  • ADAR1 prevents small intestinal injury from inflammation in a murine model of sepsis
    Shanshou Liu, Jiangang Xie, Bin Zhao, Xiaomin Hu, Xiao Li, Bin Zhang, Xianqi Wang, Yanjun Wang, Jinquan Jiang, Wen Yin, Junjie Li
    Cytokine.2018; 104: 30.     CrossRef
  • 10,741 View
  • 422 Download
  • 19 Web of Science
  • 21 Crossref
Close layer
Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery
Soo Kyung Ahn, Min Kyoon Kim, Jongjin Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, Young Joon Kang, Jisun Kim, Hyeong-Gon Moon, Jung Min Chang, Nariya Cho, Woo Kyung Moon, In Ae Park, Dong-Young Noh, Wonshik Han
Cancer Res Treat. 2017;49(4):1088-1096.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.473
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The American College of Surgeons Oncology Group Z0011 trial reported that complete dissection of axillary lymph nodes (ALNs) may not be warranted in women with clinical T1-T2 tumors and one or two involved ALNs who were undergoing lumpectomy plus radiation followed by systemic therapy. The present study was conducted to identify preoperative imaging predictors of ≥ 3 ALNs.
Materials and Methods
The training set consisted of 1,917 patients with clinical T1-T2 and node negative invasive breast cancer. Factors associated with ≥ 3 involved ALNs were evaluated by logistic regression analysis. The validation set consisted of 378 independent patients. The nomogram was applied prospectively to 512 patients who met the Z0011 criteria.
Results
Of the 1,917 patients, 204 (10.6%) had ≥ 3 positive nodes. Multivariate analysis showed that involvement of ≥ 3 nodes was significantly associated with ultrasonographic and chest computed tomography findings of suspicious ALNs (p < 0.001 each). These two imaging criteria, plus patient age, were used to develop a nomogram calculating the probability of involvement of ≥ 3 ALNs. The areas under the receiver operating characteristic curve of the nomogram were 0.852 (95% confidence interval [CI], 0.820 to 0.883) for the training set and 0.896 (95% CI, 0.836 to 0.957) for the validation set. Prospective application of the nomogram showed that 60 of 512 patients (11.7%) had scores above the cut-off. Application of the nomogram reduced operation time and cost, with a very low re-operation rate (1.6%).
Conclusion
Patients likely to have ≥ 3 positive ALNs could be identified by preoperative imaging. The nomogram was helpful in selective intraoperative examination of sentinel lymph nodes.

Citations

Citations to this article as recorded by  
  • Predicting three or more metastatic nodes using contrast-enhanced lymphatic US findings in early breast cancer
    Zihan Niu, Yunxia Hao, Yuanjing Gao, Jing Zhang, Mengsu Xiao, Feng Mao, Yidong Zhou, Ligang Cui, Yuxin Jiang, Qingli Zhu
    Insights into Imaging.2024;[Epub]     CrossRef
  • Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with ≥ 3 positive sentinel lymph nodes based on machine-learning algorithms
    Xiangli Xie, Yutong Fang, Lifang He, Zexiao Chen, Chunfa Chen, Huancheng Zeng, Bingfeng Chen, Guangsheng Huang, Cuiping Guo, Qunchen Zhang, Jundong Wu
    BMC Cancer.2024;[Epub]     CrossRef
  • Gail model and fifth edition of ultrasound BI‐RADS help predict axillary lymph node metastasis in breast cancer—A multicenter prospective study
    Lu‐Ying Gao, Hai‐Tao Ran, You‐Bin Deng, Bao‐Ming Luo, Ping Zhou, Wu Chen, Yu‐Hong Zhang, Jian‐Chu Li, Hong‐Yan Wang, Yu‐Xin Jiang
    Asia-Pacific Journal of Clinical Oncology.2023;[Epub]     CrossRef
  • Nomogram based on multiparametric analysis of early‐stage breast cancer: Prediction of high burden metastatic axillary lymph nodes
    Ling Li, Jing Zhao, Yu Zhang, Zhanyu Pan, Jin Zhang
    Thoracic Cancer.2023; 14(35): 3465.     CrossRef
  • Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer
    Jieying Chen, Xiaolian Su, Tingting Xu, Qifeng Luo, Lin Zhang, Guangyu Tang
    Future Oncology.2022; 18(15): 1849.     CrossRef
  • ACR Appropriateness Criteria® Imaging of the Axilla
    Huong T. Le-Petross, Priscilla J. Slanetz, Alana A. Lewin, Jean Bao, Elizabeth H. Dibble, Mehra Golshan, Jessica H. Hayward, Charlotte D. Kubicky, A. Marilyn Leitch, Mary S. Newell, Christine Prifti, Matthew F. Sanford, John R. Scheel, Richard E. Sharpe,
    Journal of the American College of Radiology.2022; 19(5): S87.     CrossRef
  • Avoiding unnecessary intraoperative sentinel lymph node frozen section biopsy of patients with early breast cancer
    Jongwon Kang, Tae-Kyung Yoo, Ahwon Lee, Jun Kang, Chang Ik Yoon, Bong Joo Kang, Sung Hun Kim, Woo Chan Park
    Annals of Surgical Treatment and Research.2022; 102(5): 241.     CrossRef
  • A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery
    Young-Joon Kang, Jung Hyun Park, Young Wook Ju, Kyoung-Eun Kim, Yumi Kim, Eunshin Lee, Han-Byoel Lee, Dong-Young Noh, Wonshik Han
    Scientific Reports.2022;[Epub]     CrossRef
  • Accurate Evaluation of Feature Contributions for Sentinel Lymph Node Status Classification in Breast Cancer
    Angela Lombardi, Nicola Amoroso, Loredana Bellantuono, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Daniele La Forgia, Vito Lorusso, Alfonso Monaco, Sabina Tangaro, Francesco Alfredo Zito, Roberto Bellotti, Raffaella Massafra
    Applied Sciences.2022; 12(14): 7227.     CrossRef
  • Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?
    Bhoowit Lerttiendamrong, Nattanan Treeratanapun, Voranaddha Vacharathit, Kasaya Tantiphlachiva, Phuphat Vongwattanakit, Sopark Manasnayakorn, Mawin Vongsaisuwon
    Breast Cancer: Targets and Therapy.2022; Volume 14: 281.     CrossRef
  • Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer
    Sheng-Kai Geng, Shao-Mei Fu, Hong-Wei Zhang, Yi-Peng Fu
    BMC Cancer.2022;[Epub]     CrossRef
  • Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI
    Su Min Ha, Jung Min Chang, Soo-Yeon Kim, Su Hyun Lee, Eun Sil Kim, Yeon Soo Kim, Nariya Cho, Woo Kyung Moon
    Breast Cancer Research and Treatment.2021; 186(2): 463.     CrossRef
  • Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study
    Annarita Fanizzi, Domenico Pomarico, Angelo Paradiso, Samantha Bove, Sergio Diotaiuti, Vittorio Didonna, Francesco Giotta, Daniele La Forgia, Agnese Latorre, Maria Irene Pastena, Pasquale Tamborra, Alfredo Zito, Vito Lorusso, Raffaella Massafra
    Cancers.2021; 13(2): 352.     CrossRef
  • Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features
    Annarita Fanizzi, Vito Lorusso, Albino Biafora, Samantha Bove, Maria Colomba Comes, Cristian Cristofaro, Maria Digennaro, Vittorio Didonna, Daniele La Forgia, Annalisa Nardone, Domenico Pomarico, Pasquale Tamborra, Alfredo Zito, Angelo Virgilio Paradiso,
    Applied Sciences.2021; 11(21): 10372.     CrossRef
  • The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011
    Eunjung Kong, Jungeun Choi
    Nuclear Medicine Communications.2021; 42(12): 1369.     CrossRef
  • Clinical Value of Axillary Ultrasonography in Breast Cancer with Lymph Node Metastases
    Jung Ho Park, Hyun Ryung Kim, Sanghwa Kim, Young Ah Lim, Kyoonsoon Jung, Lee Su Kim
    Journal of Surgical Ultrasound.2021; 8(2): 41.     CrossRef
  • Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer?
    V. Madekivi, P. Boström, A. Karlsson, R. Aaltonen, E. Salminen
    Acta Oncologica.2020; 59(6): 689.     CrossRef
  • External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients
    Antonio Piñero-Madrona, Francisco Ripoll-Orts, José Ignacio Sánchez-Méndez, Asunción Chaves-Benito, Maximiliano Rodrigo Gómez-de la Bárcena, Ana Calatrava-Fons, Salomón Menjón-Beltrán, Vicente Peg-Cámara
    Breast Cancer Research and Treatment.2020; 181(2): 339.     CrossRef
  • Axillary Nodal Evaluation in Breast Cancer: State of the Art
    Jung Min Chang, Jessica W. T. Leung, Linda Moy, Su Min Ha, Woo Kyung Moon
    Radiology.2020; 295(3): 500.     CrossRef
  • Can We Identify or Exclude Extensive Axillary Nodal Involvement in Breast Cancer Patients Preoperatively?
    Martijn Leenders, Gaëlle Kramer, Kamar Belghazi, Katya Duvivier, Petrousjka van den Tol, Hermien Schreurs
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Computer-aided prediction model for axillary lymph node metastasis in breast cancer using tumor morphological and textural features on ultrasound
    Woo Kyung Moon, I-Ling Chen, Ann Yi, Min Sun Bae, Sung Ui Shin, Ruey-Feng Chang
    Computer Methods and Programs in Biomedicine.2018; 162: 129.     CrossRef
  • The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer
    Sofia E Triantafillidou
    Hellenic Journal of Surgery.2018; 90(4): 186.     CrossRef
  • Axillary Lymph Node to Primary Breast Tumor Standardized Uptake Value Ratio from FDG-PET/CT Imaging for Predicting the Necessity for Nodal Dissection in Primary Breast Tumors
    Han-kyul Shin, Min Kyoon Kim, Sung Jun Park, Ju Won Seok, Hee-Chul Shin
    Journal of Breast Disease.2017; 5(2): 76.     CrossRef
  • 10,480 View
  • 354 Download
  • 21 Web of Science
  • 23 Crossref
Close layer
Comparison of the Clinical Outcomes of Patients with Squamous Cell Carcinoma of the Tonsil Receiving Postoperative Ipsilateral Versus Bilateral Neck Radiotherapy: A Propensity Score Matching Analysis (KROG 11-07)
Youngkyong Kim, Kwan Ho Cho, Sung Ho Moon, Chang Geol Lee, Ki Chang Keum, Sang-wook Lee, Yong Chan Ahn, Dongryul Oh, Yeon-Sil Kim, Yong Kyun Won, Hong-Gyun Wu, J. Hun Hah, Young-Taek Oh
Cancer Res Treat. 2017;49(4):1097-1105.   Published online February 9, 2017
DOI: https://doi.org/10.4143/crt.2016.425
AbstractAbstract PDFPubReaderePub
Purpose
The impact of postoperative ipsilateral neck radiotherapy (INRT) versus bilateral neck radiotherapy (BNRT) on the clinical outcomes of patients with tonsillar squamous cell carcinoma was analyzed retrospectively.
Materials and Methods
Between October 2001 and June 2012, 241 patients with T1-2 and N0-N2b tonsillar carcinoma from 16 institutes underwent postoperative INRT (n=84) or BNRT (n=157) following a tonsillectomy. Seventy patientswere identified from each group by propensity score matching and compared in terms of the overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates calculated using the Kaplan-Meier method with a log-rank test.
Results
The median follow-up was 55 months (range, 3 to 133 months). The survival outcomes in the INRT and BNRT groupswere similar: 5-year OS (92.8% vs. 94.0%, p=0.985), DFS (80.5% vs. 94.2%. p=0.085), LRRFS (88.1% vs. 97.1%, p=0.083), and DMFS (92.7% vs. 97.0%, p=0.370). Subgroup analysis revealed no contralateral neck recurrence in 61 patients with T1-2N0-2a regardless of the treatment groups. For 79 patients with N2b, contralateral neck recurrence was more common in the INRT group than in the BNRT group (7.9% vs. 0.0%), but the difference was not significant (p=0.107). The overall grade ≥ 2 toxicities were lower in the INRT group: acute (45.7% vs. 74.3%, p=0.001) and late (4.3% vs. 31.4%, p < 0.001), respectively.
Conclusion
INRT is an attractive strategy for patients with T1-2N0-2a tonsillar carcinoma compared to BNRT. For patients with N2b, there was a small risk of contralateral neck recurrence when treated with INRT, but its impact on the OS was limited with successful salvage treatment.

Citations

Citations to this article as recorded by  
  • A multi‐institutional feasibility lead‐in trial of lymphatic mapping with SPECT–CT for evaluating contralateral disease in lateralized oropharynx cancer using 99m‐technetium sulfur colloid
    Leba Michael Sarkis, Christopher MKL Yao, Aaron Hendler, Ravi Mohan, Michael Au, Han Zhang, Antoine Eskander, Kevin Higgins, Danielle MacNeil, Sharon Tzelnick, David Goldstein, Ali Hosni, John R. de Almeida
    Head & Neck.2024;[Epub]     CrossRef
  • Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
    Danielle N. Margalit, Christopher J. Anker, Michalis Aristophanous, Musaddiq Awan, Gopal K. Bajaj, Lisa Bradfield, Joseph Califano, Jimmy J. Caudell, Christina H. Chapman, Adam S. Garden, Paul M. Harari, Amanda Helms, Alexander Lin, Ellie Maghami, Ranee M
    Practical Radiation Oncology.2024; 14(5): 398.     CrossRef
  • Proton pencil beam scanning radiotherapy in the postoperative treatment of p16 positive squamous cell tonsillar cancer – evaluation of toxicity and effectivity
    Jiří Kubeš, Sarah Al-Hamami, Silvia Sláviková, Pavel Vítek, Alexandra Haas, Kateřina Dědečková, Barbora Ondrová, Michal Andrlik, Matěj Navrátil, Eliška Rotnáglová, Vladimír Vondráček
    European Archives of Oto-Rhino-Laryngology.2024; 281(10): 5447.     CrossRef
  • Unilateral radiotherapy for tonsillar cancer with multiple ipsilateral neck lymph nodes
    Tae Hyun Kim, Hong-Gyun Wu, Soon-Hyun Ahn, Woo-Jin Jeong, Wonjae Cha, Keun-Yong Eom
    Radiation Oncology Journal.2024; 42(3): 192.     CrossRef
  • Impact of Postoperative Neck Radiotherapy Volumes on Long‐Term Unstimulated Saliva Flow Following Primary Surgery and Ipsilateral Neck Dissection for Oral Cavity Squamous Cell Carcinoma
    Claire M. Rooney, Shao Hui Huang, Jie Su, Scott Bratman, John Cho, John de Almeida, Michael Glogauer, David Goldstein, Ezra Hahn, Ali Hosni, Andrew Hope, Jonathan Irish, John Kim, Brian O'Sullivan, Jolie Ringash, Anna Spreafico, Jillian Tsai, John Waldron
    Head & Neck.2024;[Epub]     CrossRef
  • Association of Unilateral Radiotherapy With Contralateral Lymph Node Failure Among Patients With Squamous Cell Carcinoma of the Tonsil
    Niema B. Razavian, Ralph B. D’Agostino, Cole R. Steber, Corbin A. Helis, Ryan T. Hughes
    JAMA Network Open.2023; 6(2): e2255209.     CrossRef
  • Low contralateral neck recurrence risk with ipsilateral neck radiotherapy in N2b tonsillar squamous cell carcinoma
    Divya Natesan, Christina K. Cramer, Taofik Oyekunle, Donna Niedzwiecki, David M. Brizel, Yvonne M. Mowery
    Oral Oncology.2023; 139: 106362.     CrossRef
  • Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits
    Jared H Hara, Stanley I Gutiontov, Sophia Uddin, Ari J Rosenberg, Alexander T Pearson, Zhen Gooi, Elizabeth A Blair, Nishant Agrawal, Everett E Vokes, Daniel T Ginat, Daniel J Haraf, Aditya Juloori
    Cureus.2022;[Epub]     CrossRef
  • Evaluating contralateral neck failure in patients with lateralized OPSCC treated with transoral robotic surgery and neck management based on pre-operative SPECT-CT lymphatic mapping
    Ilyes Berania, Ali Hosni, Carissa M. Thomas, David Goldstein, Andrew Bayley, Ravi Mohan, Aaron Hendler, Richard M. Cooper, John R. de Almeida
    Journal of Otolaryngology - Head & Neck Surgery.2022;[Epub]     CrossRef
  • Short‐term and long‐term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma
    Shao Hui Huang, John R. de Almeida, Erin Watson, Michael Glogauer, Wei Xu, Sareh Keshavarzi, Brian O'Sullivan, Jolie Ringash, Andrew Hope, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, John Kim, John Waldron, Anna Spreafico, David P Goldst
    Head & Neck.2021; 43(2): 456.     CrossRef
  • Ipsilateral radiation for squamous cell carcinoma of the tonsil: American Radium Society appropriate use criteria executive summary
    C. Jillian Tsai, Thomas J. Galloway, Danielle N. Margalit, Richard L. Bakst, Beth M. Beadle, Jonathan J. Beitler, Steven Chang, Allen Chen, Jay Cooper, Shlomo A. Koyfman, John A. Ridge, Jared Robbins, Minh Tam Truong, Sue S. Yom, Farzan Siddiqui
    Head & Neck.2021; 43(1): 392.     CrossRef
  • Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma
    Ali Hosni, Shao Hui Huang, Wei Xu, Jie Su, Erin Watson, Michael Glogauer, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Brian O'Sullivan, Jolie Ringash, Anna Spreafico, David P. Goldstein, John Waldron, John R. de Al
    Radiotherapy and Oncology.2021; 156: 95.     CrossRef
  • Refining Guidelines Regarding Unilateral Treatment in Patients With Well-lateralized Squamous Cell Carcinoma of the Palatine Tonsil and Multiple Positive Nodes or Extranodal Extension
    Robert J. Amdur, Paul M. Harari, Peter T. Dziegielewski, William M. Mendenhall
    Practical Radiation Oncology.2021; 11(3): e247.     CrossRef
  • Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck
    Sandra Nuyts, Heleen Bollen, Avrahram Eisbruch, June Corry, Primoz Strojan, Antti A. Mäkitie, Johannes A. Langendijk, William M. Mendenhall, Robert Smee, Remco DeBree, Anne W. M. Lee, Alessandra Rinaldo, Alfio Ferlito
    Head & Neck.2021; 43(9): 2807.     CrossRef
  • The treatment of tonsillar squamous cell carcinoma at Hue Central Hospital
    Phuong Nam Tran
    Journal of Clinical Medicine- Hue Central Hospital.2021;[Epub]     CrossRef
  • Efficacy of Postoperative Unilateral Neck Irradiation in Patients with Buccal Mucosa Squamous Carcinoma with Extranodal Extension: A Propensity Score Analysis
    Chia-Hsin Lin, Chien-Yu Lin, Kang-Hsing Fan, Sheng-Ping Hung, Yung-Chih Chou, Chia-Jen Liu, Wen-Chi Chou, Yen-Chao Chen, Shiang-Fu Huang, Chung-Jan Kang, Kai-Ping Chang, Hung-Ming Wang, Ann-Joy Cheng, Joseph Tung-Chieh Chang
    Cancers.2021; 13(23): 5997.     CrossRef
  • Contralateral nodal failures in oropharyngeal cancers after TORS and unilateral neck management: A retrospective study
    Axel Sahovaler, John J. W. Lee, Wei Xu, Susie Su, Ali Hosni, Andrew Bayley, David P. Goldstein, John R. de Almeida
    Journal of Otolaryngology - Head & Neck Surgery.2021;[Epub]     CrossRef
  • Lymphatic mapping with SPECT‐CT for evaluation of contralateral drainage in lateralized oropharyngeal cancers using an awake injection technique
    Carissa M. Thomas, Mohemmed N. Khan, Ravi Mohan, Aaron Hendler, Ali Hosni, Douglas B. Chepeha, David P. Goldstein, Richard M Cooper, John R. de Almeida
    Head & Neck.2020; 42(3): 385.     CrossRef
  • Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck
    Hidenori Kimura, Satoshi Hamauchi, Sadayuki Kawai, Yusuke Onozawa, Hirofumi Yasui, Aiko Yamashita, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Tomoya Yokota
    International Journal of Clinical Oncology.2020; 25(2): 258.     CrossRef
  • Désescalade thérapeutique dans les cancers de l’oropharynx induit par les HPV : mise au point
    C. Lahmamssi, J.-B. Guy, N. Benchekroun, Z. Bouchbika, N. Taoufik, H. Jouhadi, S. Sahraoui, A. Benider, M. Ben Mrad, O. Jmour, A. Bousarsar, M.L. Lan, Q. Lei, M. Benna, D. Moslemi, A. Vallard, N. Magné
    Cancer/Radiothérapie.2020; 24(3): 258.     CrossRef
  • The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors
    Sonja Stieb, Ismael Perez-Martinez, Abdallah S.R. Mohamed, Stockton Rock, Nimit Bajaj, Tanaya S. Deshpande, Mohamed Zaid, Adam S. Garden, Ryan P. Goepfert, Richard Cardoso, Renata Ferrarotto, Jay P. Reddy, Jack Phan, William H. Morrison, David I. Rosentha
    Clinical and Translational Radiation Oncology.2020; 24: 71.     CrossRef
  • Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy?
    Yonca Onbasi, Sebastian Lettmaier, Markus Hecht, Sabine Semrau, Heinrich Iro, Marco Kesting, Rainer Fietkau, Marlen Haderlein
    Strahlentherapie und Onkologie.2019; 195(6): 482.     CrossRef
  • Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update
    Julian Biau, Michel Lapeyre, Idriss Troussier, Wilfried Budach, Jordi Giralt, Cai Grau, Joanna Kazmierska, Johannes A. Langendijk, Mahmut Ozsahin, Brian O'Sullivan, Jean Bourhis, Vincent Grégoire
    Radiotherapy and Oncology.2019; 134: 1.     CrossRef
  • Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer
    Jared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, John N Lukens, Samuel Swisher-McClure, Gregory S Weinstein, Bert W O’Malley Jr, Ara A Chalian, Christopher H Rassekh, Jason G Newman, Roger B Cohen, Joshua M Bauml, Charu Aggarwal, Alexander Lin
    The British Journal of Radiology.2019;[Epub]     CrossRef
  • 9,768 View
  • 314 Download
  • 22 Web of Science
  • 24 Crossref
Close layer
Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries
Yanxia Li, Liya Yu, Jun Na, Shuang Li, Li Liu, Huijuan Mu, Xuanjuan Bi, Xiaoxia An, Xun Li, Wen Dong, Guowei Pan
Cancer Res Treat. 2017;49(4):1106-1113.   Published online February 2, 2017
DOI: https://doi.org/10.4143/crt.2016.613
AbstractAbstract PDFPubReaderePub
Purpose
The cancer survival was characterized by following up sampled subgroups of cancer cases from three population-based cancer registries in Northeast China.
Materials and Methods
Survival analysis was used to analyze 6,871 patients, who had one of the 21 most common cancers based on sampling from the population-based cancer registries of three cities in Liaoning Province. All patients were diagnosed between 2000 and 2002 and were followed up to the end of 2007 by active and passive methods. The 5-year age standardized relative survival rates (ASRS) were estimated for all cancers combined and each of the 21 individual cancers.
Results
The survival status was traced for 80.8% of 8,506 sampled cancer cases. The 5-year ASRS for all 21 cancers combined was 41.5% (95% confidence interval, 40.3 to 42.7), the highest ASRS was observed for thyroid cancer (85.2%), breast cancer (78.9%), uterine corpus cancer (75.9%), and urinary bladder cancer (70.2%); the lowest 5-year ASRS was noted in pancreatic cancer (8.8%), liver cancer (11.0%), esophageal cancer (18.8), and lung cancer (19.6%). The cancer survival rates in Liaoning cities were similar to those of urban areas in mainland China, but significantly lower than those in Hong Kong, Korea, and Japan.
Conclusion
The strikingly poor cancer survival rates in three cities of Liaoning Province and in other places in China highlight the need for urgent investment in cancer prevention, early detection, and standardized and centralized treatment.

Citations

Citations to this article as recorded by  
  • Cancer Survival Trends in Southeastern China, 2011–2021: A Population-Based Study
    Yan Zhou, Yeying Wen, Zhisheng Xiang, Jingyu Ma, Yongtian Lin, Yongying Huang, Chuanben Chen
    Clinical Epidemiology.2024; Volume 16: 45.     CrossRef
  • Identification of m6a-related signature genes in esophageal squamous cell carcinoma by machine learning method
    Qi-Xin Shang, Wei-Li Kong, Wen-Hua Huang, Xin Xiao, Wei-Peng Hu, Yu-Shang Yang, Hanlu Zhang, Lin Yang, Yong Yuan, Long-Qi Chen
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China
    Changlian Chen, Jiayan Cao, Yueyang Wang, Xuya Han, Yaju Zhang, Shumei Zhuang
    Thyroid.2023; 33(4): 474.     CrossRef
  • Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study
    Soheil Hassanipour, Reza Zare, Alireza Shahedi, Hamed Delam
    Endocrine.2023; 82(2): 237.     CrossRef
  • Trends of stomach cancer survival: A systematic review of survival rates from population‐based cancer registration
    Jia Yi Tuo, Jing Hao Bi, Hui Yun Yuan, Yu Fei Jiang, Xiao Wei Ji, Hong Lan Li, Yong Bing Xiang
    Journal of Digestive Diseases.2022; 23(1): 22.     CrossRef
  • Research Progress in Immunotherapy of Esophageal Squamous Carcinoma
    彩耘 李
    Advances in Clinical Medicine.2022; 12(01): 545.     CrossRef
  • FOXD3 and GAB2 as a pair of rivals antagonistically control hepatocellular carcinogenesis
    Ruimin Liu, Yan Sun, Shuai Chen, Yun Hong, Zhongxian Lu
    The FEBS Journal.2022; 289(15): 4536.     CrossRef
  • Current status of premature mortality from four non-communicable diseases and progress towards the Sustainable Development Goal target 3.4: a population-based study in northeast China, 2004–2017
    Li Liu, Yanxia Li, Junmin Song, Qian Chen, Shuang Li, Huijuan Mu, Jun Na, Rui Zhang, Liya Yu, Wei Sun, Guowei Pan
    BMC Public Health.2021;[Epub]     CrossRef
  • Utility of Circulating Tumor Cells for Detection of Early-Stage Luminal A Breast Cancer
    Yang Zhang, Ji Qi, Jianyi Li, Shi Jia, Yitong Wang, Qiang Sun, Ye Kang, Yushi Liu, Yanan Cao, Jiaxin Yu
    The American Journal of the Medical Sciences.2020; 360(5): 543.     CrossRef
  • Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade
    Jianjun Yang, Xiguang Liu, Sai Cao, Xiaoying Dong, Shuan Rao, Kaican Cai
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Cancer survival in Cixian of China, 2003–2013: a population‐based study
    Dongfang Li, Daojuan Li, Guohui Song, Di Liang, Chao Chen, Yachen Zhang, Zhaoyu Gao, Yutong He
    Cancer Medicine.2018; 7(4): 1537.     CrossRef
  • Dosimetric comparison between helical tomotherapy and intensity‐modulated radiotherapy for esophageal carcinoma
    Qing Gu, Xiao‐jing Lai, Shuang‐yan Yang, Wei Feng, Xiao Lin, Xiao‐fu Yu, Xiao Zheng
    Precision Radiation Oncology.2017; 1(3): 88.     CrossRef
  • 22,000 View
  • 196 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Education Level Is a Strong Prognosticator in the Subgroup Aged More Than 50 Years Regardless of the Molecular Subtype of Breast Cancer: A Study Based on the Nationwide Korean Breast Cancer Registry Database
Ki-Tae Hwang, Woochul Noh, Se-Heon Cho, Jonghan Yu, Min Ho Park, Joon Jeong, Hyouk Jin Lee, Jongjin Kim, Sohee Oh, Young A Kim, Korean Breast Cancer Society
Cancer Res Treat. 2017;49(4):1114-1126.   Published online February 2, 2017
DOI: https://doi.org/10.4143/crt.2016.528
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study investigated the role of the education level (EL) as a prognostic factor for breast cancer and analyzed the relationship between the EL and various confounding factors.
Materials and Methods
The data for 64,129 primary breast cancer patients from the Korean Breast Cancer Registry were analyzed. The EL was classified into two groups according to the education period; the high EL group (≥ 12 years) and low EL group (< 12 years). Survival analyses were performed with respect to the overall survival between the two groups.
Results
A high EL conferred a superior prognosis compared to a low EL in the subgroup aged > 50 years (hazard ratio, 0.626; 95% confidence interval [CI], 0.577 to 0.678) but not in the subgroup aged ≤ 50 years (hazard ratio, 0.941; 95% CI, 0.865 to 1.024). The EL was a significant independent factor in the subgroup aged > 50 years according to multivariate analyses. The high EL group showed more favorable clinicopathologic features and a higher proportion of patients in this group received lumpectomy, radiation therapy, and endocrine therapy. In the high EL group, a higher proportion of patients received chemotherapy in the subgroups with unfavorable clinicopathologic features. The EL was a significant prognosticator across all molecular subtypes of breast cancer.
Conclusion
The EL is a strong independent prognostic factor for breast cancer in the subgroup aged > 50 years regardless of the molecular subtype, but not in the subgroup aged ≤ 50 years. Favorable clinicopathologic features and active treatments can explain the main causality of the superior prognosis in the high EL group.

Citations

Citations to this article as recorded by  
  • Risk factors for intensive care unit readmission after lung transplantation: a retrospective cohort study
    Hye-Bin Kim, Sungwon Na, Hyo Chae Paik, Hyeji Joo, Jeongmin Kim
    Acute and Critical Care.2021; 36(2): 99.     CrossRef
  • Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors
    Wang‐Zhong Li, Guo‐Ying Liu, Shu‐Hui Lv, Sen‐Kui Xu, Hu Liang, Kui‐Yuan Liu, Meng‐Yun Qiang, Xi Chen, Xiang Guo, Xing Lv, Wei‐Xiong Xia, Yan‐Qun Xiang
    Clinical and Translational Medicine.2020;[Epub]     CrossRef
  • Education level as a predictor of survival in patients with multiple myeloma
    Limei Xu, Xiuju Wang, Xueyi Pan, Xiaotao Wang, Qing Wang, Bingyi Wu, Jiahui Cai, Ying Zhao, Lijuan Chen, Wuping Li, Juan Li
    BMC Cancer.2020;[Epub]     CrossRef
  • Prognostic influence of Korean public medical insurance system on breast cancer patients
    Ki-Tae Hwang, Young Wook Ju, Young A Kim, Jongjin Kim, Sohee Oh, Jiwoong Jung, Young Jun Chai, In Sil Choi, So Won Oh
    Annals of Surgical Treatment and Research.2019; 96(2): 58.     CrossRef
  • 9,317 View
  • 170 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer
Hyung Soon Park, Ji Soo Park, You Jin Chun, Yun Ho Roh, Jieun Moon, Hong Jae Chon, Hye Jin Choi, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Hei-Cheul Jeung
Cancer Res Treat. 2017;49(4):1127-1139.   Published online February 6, 2017
DOI: https://doi.org/10.4143/crt.2016.538
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Metastatic biliary tract cancer (mBTC) has a dismal prognosis. In this study, an independent dataset of patients with mBTC was used to implement and validate a routine clinico-laboratory parameter-based scoring model for risk group identification.
Materials and Methods
From September 2006 to February 2015, 482 patients with mBTC were assigned randomly (ratio, 7:3) into investigational (n=340) and validation datasets (n=142). The continuous variables were dichotomized using a normal range or the best cutoff values determined using the Contal and O'Quigley statistical methods. Following a Cox’s proportional hazard model, the scoring model was derived by summing the rounded chi-square scores for the factors identified by multivariate analysis.
Results
The performance status (Eastern Cooperative Oncology Group 3-4), hypoalbuminemia (< 3.4 mg/dL), carcinoembryonic antigen (≥ 9 ng/mL), neutrophil-to-lymphocyte ratio (≥ 3.0), and carbohydrate antigen 19-9 (≥ 120 U/mL) were identified as independent prognosticators (Harrell’s C index, 0.682; integrated area under the curve, 0.653). Survival was clearly correlated with the risk groups (low, intermediate, and high, 14.0, 7.3, and 2.3 months, respectively; p < 0.001). The prognosis was also discriminative in the validation data set (median survival, 16.7, 7.5, and 1.9 months, respectively; p < 0.001). Chemotherapy did not offer any survival benefits for high-risk patients.
Conclusion
These proposed prognostic criteria for mBTC can facilitate accurate patient risk stratification and treatment-related decision-making.

Citations

Citations to this article as recorded by  
  • A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
    Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang, Miao Chen, Wei Cao, Hongfeng Gou, Qing Zhu
    Cancer Research and Treatment.2024; 56(2): 602.     CrossRef
  • Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy
    Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski, Vaibhav Sahai
    The Oncologist.2023; 28(6): 531.     CrossRef
  • Development of a nomogram to predict survival in advanced biliary tract cancer
    Hiroshi Imaoka, Masafumi Ikeda, Shogo Nomura, Chigusa Morizane, Takuji Okusaka, Masato Ozaka, Satoshi Shimizu, Kentaro Yamazaki, Naohiro Okano, Kazuya Sugimori, Hirofumi Shirakawa, Nobumasa Mizuno, Sohei Satoi, Hironori Yamaguchi, Rie Sugimoto, Kunihito G
    Scientific Reports.2023;[Epub]     CrossRef
  • Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
    Giulia Rovesti, Francesco Leone, Giovanni Brandi, Lorenzo Fornaro, Mario Scartozzi, Monica Niger, Changhoon Yoo, Francesco Caputo, Roberto Filippi, Mariaelena Casagrande, Nicola Silvestris, Daniele Santini, Luca Faloppi, Andrea Palloni, Massimo Aglietta,
    Journal of Gastrointestinal Cancer.2022; 53(2): 289.     CrossRef
  • Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis
    Roberto Filippi, Francesco Leone, Lorenzo Fornaro, Giuseppe Aprile, Andrea Casadei-Gardini, Nicola Silvestris, Andrea Palloni, Maria Antonietta Satolli, Mario Scartozzi, Marco Russano, Stefania Eufemia Lutrino, Pasquale Lombardi, Giorgio Frega, Silvio Ken
    Journal of Chemotherapy.2022; 34(2): 123.     CrossRef
  • Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
    Pedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn, Jason S. Starr, Jeremy C. Jones, Hani Babiker, Samantha R. Inabinett, Natasha Wylie, Ashton W.R. Boyle, Tanios S. Bekaii-Saab, Gregory J. Gores, Ror
    JCO Precision Oncology.2022;[Epub]     CrossRef
  • Pre-treatment Nutritional Risk Assessment by NRS-2002 Predicts Prognosis in Patients With Advanced Biliary Tract Cancer: A Single Center Retrospective Study
    Se Eung Oh, Juong Soon Park, Hei-Cheul Jeung
    Clinical Nutrition Research.2022; 11(3): 183.     CrossRef
  • Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC
    Jyotsna Singh, Durgesh Shukla, Sanjiv Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari
    Cancer Treatment and Research Communications.2021; 28: 100431.     CrossRef
  • A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
    Roberto Filippi, Francesco Montagnani, Pasquale Lombardi, Lorenzo Fornaro, Giuseppe Aprile, Andrea Casadei-Gardini, Luca Faloppi, Andrea Palloni, Maria Antonietta Satolli, Mario Scartozzi, Fabrizio Citarella, Stefania Eufemia Lutrino, Caterina Vivaldi, Ni
    Acta Oncologica.2021; 60(10): 1317.     CrossRef
  • Second-line therapies in advanced biliary tract cancers
    Sri Harsha Tella, Anuhya Kommalapati, Mitesh J Borad, Amit Mahipal
    The Lancet Oncology.2020; 21(1): e29.     CrossRef
  • The neonatal Fc receptor in cancer FcRn in cancer
    Diana Cadena Castaneda, Guillaume Brachet, Caroline Goupille, Lobna Ouldamer, Valérie Gouilleux‐Gruart
    Cancer Medicine.2020; 9(13): 4736.     CrossRef
  • Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients
    Byung min Lee, Yeona Cho, Jun Won Kim, Hei Cheul Jeung, Ik Jae Lee
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Construction of a Five-Super-Enhancer-Associated-Genes Prognostic Model for Osteosarcoma Patients
    Zhanbo Ouyang, Guohua Li, Haihong Zhu, Jiaojiao Wang, Tingting Qi, Qiang Qu, Chao Tu, Jian Qu, Qiong Lu
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
    Yuko Suzuki, Motoyasu Kan, Gen Kimura, Kumiko Umemoto, Kazuo Watanabe, Mitsuhito Sasaki, Hideaki Takahashi, Yusuke Hashimoto, Hiroshi Imaoka, Izumi Ohno, Shuichi Mitsunaga, Masafumi Ikeda
    Journal of Gastroenterology.2019; 54(3): 281.     CrossRef
  • Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
    Min su You, Ji Kon Ryu, Young Hoon Choi, Jin Ho Choi, Gunn Huh, Woo Hyun Paik, Sang Hyub Lee, Yong-Tae Kim
    BMC Cancer.2019;[Epub]     CrossRef
  • Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study
    Anna Song, Wankyu Eo, Sehyun Kim, Bumsang Shim, Sookyung Lee
    BMC Complementary and Alternative Medicine.2018;[Epub]     CrossRef
  • Platelet to lymphocyte ratio in biliary tract cancer: Review and meta-analysis
    Lin-hua Zhou, Xiao-feng Luo
    Clinica Chimica Acta.2017; 474: 102.     CrossRef
  • 11,410 View
  • 259 Download
  • 17 Web of Science
  • 17 Crossref
Close layer
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jörg U. Schmohl, Martin Felices, Felix Oh, Alexander J. Lenvik, Aaron M. Lebeau, Jayanth Panyam, Jeffrey S. Miller, Daniel A. Vallera
Cancer Res Treat. 2017;49(4):1140-1152.   Published online February 20, 2017
DOI: https://doi.org/10.4143/crt.2016.491
AbstractAbstract PDFPubReaderePub
Purpose
The selective elimination of cancer stem cells (CSCs) in tumor patients is a crucial goal because CSCs cause drug refractory relapse. To improve the current conventional bispecific immune-engager platform, a 16133 bispecific natural killer (NK) cell engager (BiKE), consisting of scFvs binding FcγRIII (CD16) on NK cells and CD133 on carcinoma cells, was first synthesized and a modified interleukin (IL)-15 crosslinker capable of stimulating NK effector cells was introduced.
Materials and Methods
DNA shuffling and ligation techniques were used to assemble and synthesize the 1615133 trispecific NK cell engager (TriKE). The construct was tested for its specificity using flow cytometry, cytotoxic determinations using chromium release assays, and lytic degranulation. IL-15–mediated expansion was measured using flow-based proliferation assays. The level of interferon (IFN)-γ release was measured because of its importance in the anti-cancer response.
Results
1615133 TriKE induced NK cell–mediated cytotoxicity and NK expansion far greater than that achieved with BiKE devoid of IL-15. The drug binding and induction of cytotoxic degranulation was CD133+ specific and the anti-cancer activity was improved by integrating the IL-15 cross linker. The NK cell–related cytokine release measured by IFN-γ detection was higher than that of BiKE. NK cytokine release studies showed that although the IFN-γ levels were elevated, they did not approach the levels achieved with IL-12/IL-18, indicating that release was not at the supraphysiologic level.
Conclusion
1615133 TriKE enhances the NK cell anti-cancer activity and provides a self-sustaining mechanism via IL-15 signaling. By improving the NK cell performance, the new TriKE represents a highly active drug against drug refractory relapse mediated by CSCs.

Citations

Citations to this article as recorded by  
  • New immune cell engagers for cancer immunotherapy
    Aurore Fenis, Olivier Demaria, Laurent Gauthier, Eric Vivier, Emilie Narni-Mancinelli
    Nature Reviews Immunology.2024; 24(7): 471.     CrossRef
  • Natural killer cell therapies
    Eric Vivier, Lucas Rebuffet, Emilie Narni-Mancinelli, Stéphanie Cornen, Rob Y. Igarashi, Valeria R. Fantin
    Nature.2024; 626(8000): 727.     CrossRef
  • Tri-specific killer engager: unleashing multi-synergic power against cancer
    Peeranut Winidmanokul, Aussara Panya, Seiji Okada
    Exploration of Targeted Anti-tumor Therapy.2024; 5(2): 432.     CrossRef
  • Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases
    Camille Rolin, Jacques Zimmer, Carole Seguin-Devaux
    Cellular & Molecular Immunology.2024; 21(7): 643.     CrossRef
  • Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives
    Magdalena Rados, Anna Landegger, Lukas Schmutzler, Kimberlie Rabidou, Sabine Taschner-Mandl, Irfete S. Fetahu
    Cancer and Metastasis Reviews.2024;[Epub]     CrossRef
  • Implications of glycosylation for the development of selected cytokines and their derivatives for medical use
    Giulia Scapin, Ece Çagdas, Lise Grav, Nathan Lewis, Steffen Goletz, Lise Hafkenscheid
    Biotechnology Advances.2024; : 108467.     CrossRef
  • Emerging Antibodies in Cancer Therapy
    Yaping Sun, Jian Xu
    Advanced NanoBiomed Research.2023;[Epub]     CrossRef
  • Mapping the interplay between NK cells and HIV: therapeutic implications
    Renee R Anderko, Robbie B Mailliard
    Journal of Leukocyte Biology.2023; 113(2): 109.     CrossRef
  • Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
    Julia Harwardt, Stefania C. Carrara, Jan P. Bogen, Katrin Schoenfeld, Julius Grzeschik, Björn Hock, Harald Kolmar
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
    Xinghui Xiao, Ying Cheng, Xiaodong Zheng, Yuhang Fang, Yu Zhang, Rui Sun, Zhigang Tian, Haoyu Sun
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • NK cell defects: implication in acute myeloid leukemia
    Selma Z. D’Silva, Meenakshi Singh, Andrea S. Pinto
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
    Eunju Shin, Seong Ho Bak, Taeho Park, Jin Woo Kim, Suk-Ran Yoon, Haiyoung Jung, Ji-Yoon Noh
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
    Minchuan Zhang, Kong-Peng Lam, Shengli Xu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
    Tian Huan, Bugao Guan, Hongbo Li, Xiu Tu, Chi Zhang, Bin Tang
    Human Vaccines & Immunotherapeutics.2023;[Epub]     CrossRef
  • Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
    Titas Banerjee, Anusha Vallurupalli
    Current Problems in Cancer.2022; 46(1): 100825.     CrossRef
  • The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
    Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, Yingying Huang, Ying Cheng, Yangyang Li, Yuwei Wu, Guoshuai Cao, Zhigang Tian
    Cellular & Molecular Immunology.2022; 19(2): 192.     CrossRef
  • Engineering interferons and interleukins for cancer immunotherapy
    Patrick G. Holder, Shion A. Lim, Christine S. Huang, Preeti Sharma, Yavuz S. Dagdas, Beyza Bulutoglu, Jonathan T. Sockolosky
    Advanced Drug Delivery Reviews.2022; 182: 114112.     CrossRef
  • iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
    Benjamin H. Goldenson, Pooja Hor, Dan S. Kaufman
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy
    Wanze Zhang, Zhenghua Zhao, Fan Li
    Molecular Immunology.2022; 144: 58.     CrossRef
  • Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
    Dain Moon, Nara Tae, Yunji Park, Seung-Woo Lee, Dae Hee Kim
    Immune Network.2022;[Epub]     CrossRef
  • Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
    Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
    Nature Reviews Drug Discovery.2022; 21(8): 559.     CrossRef
  • Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
    Mubin Tarannum, Rizwan Romee, Roman M. Shapiro
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Bispecific antibodies for immune cell retargeting against cancer
    Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang, Javier Chaparro-Riggers
    Expert Opinion on Biological Therapy.2022; 22(8): 965.     CrossRef
  • The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
    Muhammad Sajid, Lianxin Liu, Cheng Sun
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Emerging Trends in Immunotherapy for Cancer
    Alok K. Mishra, Amjad Ali, Shubham Dutta, Shahid Banday, Sunil K. Malonia
    Diseases.2022; 10(3): 60.     CrossRef
  • Drug-Tolerant Persister Cells in Cancer Therapy Resistance
    Pavan Kumar Dhanyamraju, Todd D. Schell, Shantu Amin, Gavin P. Robertson
    Cancer Research.2022; 82(14): 2503.     CrossRef
  • Natural killer cells in antitumour adoptive cell immunotherapy
    Tamara J. Laskowski, Alexander Biederstädt, Katayoun Rezvani
    Nature Reviews Cancer.2022; 22(10): 557.     CrossRef
  • TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
    Michael F Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Behiye Kodal, Yvette Soignier, Peter Hinderlie, Joshua T Walker, Todd R Lenvik, Melissa A Geller, Jeffrey S Miller, Martin Felices
    Journal for ImmunoTherapy of Cancer.2022; 10(9): e004725.     CrossRef
  • The soldiers needed to be awakened: Tumor-infiltrating immune cells
    Wang Yaping, Wang Zhe, Chu Zhuling, Li Ruolei, Fan Pengyu, Guo Lili, Ji Cheng, Zhang Bo, Liu Liuyin, Hou Guangdong, Wang Yaoling, Hou Niuniu, Ling Rui
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
    Xinyu Wu, Sandro Matosevic
    Molecular Therapy - Oncolytics.2022; 27: 224.     CrossRef
  • Multiplexed engineering and precision gene editing in cellular immunotherapy
    Alexander Biederstädt, Gohar Shahwar Manzar, May Daher
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • NK cells and ILCs in tumor immunotherapy
    Simona Sivori, Daniela Pende, Linda Quatrini, Gabriella Pietra, Mariella Della Chiesa, Paola Vacca, Nicola Tumino, Francesca Moretta, Maria Cristina Mingari, Franco Locatelli, Lorenzo Moretta
    Molecular Aspects of Medicine.2021; 80: 100870.     CrossRef
  • Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
    Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise, Daniel Olive
    Journal of Leukocyte Biology.2021; 109(6): 1071.     CrossRef
  • Cancer stem cells and strategies for targeted drug delivery
    Jin Cao, Shubhmita Bhatnagar, Jiawei Wang, Xueyong Qi, Swayam Prabha, Jayanth Panyam
    Drug Delivery and Translational Research.2021; 11(5): 1779.     CrossRef
  • The role of natural killer cell in gastrointestinal cancer: killer or helper
    Feixue Wang, Jennie Ka Ching Lau, Jun Yu
    Oncogene.2021; 40(4): 717.     CrossRef
  • Next-Generation Immunotherapies to Improve Anticancer Immunity
    Yaoyao Shi, Katarzyna Tomczak, June Li, Joshua K. Ochieng, Younghee Lee, Cara Haymaker
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Engineered Multifunctional Nano‐ and Biological Materials for Cancer Immunotherapy
    Anthony Brouillard, Nilesh Deshpande, Ashish A. Kulkarni
    Advanced Healthcare Materials.2021;[Epub]     CrossRef
  • Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
    Cristina Capuano, Chiara Pighi, Simone Battella, Davide De Federicis, Ricciarda Galandrini, Gabriella Palmieri
    Cancers.2021; 13(10): 2500.     CrossRef
  • Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
    Olivier Demaria, Laurent Gauthier, Guilhaume Debroas, Eric Vivier
    European Journal of Immunology.2021; 51(8): 1934.     CrossRef
  • Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
    Gihoon You, Jonghwa Won, Yangsoon Lee, Dain Moon, Yunji Park, Sang Hoon Lee, Seung-Woo Lee
    Vaccines.2021; 9(7): 724.     CrossRef
  • Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
    Shee Kwan Phung, Jeffrey S. Miller, Martin Felices
    Molecular Diagnosis & Therapy.2021; 25(5): 577.     CrossRef
  • Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors
    Guangyu Lian, Thomas Shiu-Kwong Mak, Xueqing Yu, Hui-Yao Lan
    International Journal of Molecular Sciences.2021; 23(1): 164.     CrossRef
  • Targeting Natural Killer Cells for Tumor Immunotherapy
    Cai Zhang, Yuan Hu, Chongdeng Shi
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
    Aviad Ben-Shmuel, Guy Biber, Mira Barda-Saad
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Boosting Cytotoxic Antibodies against Cancer
    Laurent Gauthier, Eric Vivier
    Cell.2020; 180(5): 822.     CrossRef
  • Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
    Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin, Jo Caers
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
    Daniel A. Vallera, Soldano Ferrone, Behiye Kodal, Peter Hinderlie, Laura Bendzick, Brianna Ettestad, Caroline Hallstrom, Nicholas A. Zorko, Arpit Rao, Naomi Fujioka, Charles J. Ryan, Melissa A. Geller, Jeffrey S. Miller, Martin Felices
    Cancers.2020; 12(9): 2659.     CrossRef
  • Exploiting NK Cell Surveillance Pathways for Cancer Therapy
    Alexander Barrow, Marco Colonna
    Cancers.2019; 11(1): 55.     CrossRef
  • Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
    Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Natural Killer Cells in Cancer Immunotherapy
    Jeffrey S. Miller, Lewis L. Lanier
    Annual Review of Cancer Biology.2019; 3(1): 77.     CrossRef
  • Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
    Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller, Veronika Bachanova
    Blood Advances.2019; 3(6): 897.     CrossRef
  • Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses
    Mathieu J.F. Crupi, John C. Bell, Ragunath Singaravelu
    Stem Cells.2019; 37(6): 716.     CrossRef
  • Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
    Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchard-Alvarez, Gwendoline Grondin, Sylvia Trichard, Cédric Cesari, Melody Sapet, Frédéric Bosco, Hélène Rispaud-Blanc, Franceline Guillot, Stéphanie Cornen, Alain Roussel, Béatrice
    Cell.2019; 177(7): 1701.     CrossRef
  • Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
    Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Susanne Wingert, Thorsten Ross, Thomas Müller, Ute Schniegler-Mattox, Torsten Haneke, Erich Rajkovic, Joachim Koch, Martin Treder, Michael Tesar
    mAbs.2019; 11(5): 899.     CrossRef
  • T Cell–Activating Bispecific Antibodies in Cancer Therapy
    Asaad Trabolsi, Artavazd Arumov, Jonathan H. Schatz
    The Journal of Immunology.2019; 203(3): 585.     CrossRef
  • Les anticorps etscaffoldbispécifiques, des médicaments innovants en oncologie impliquant le ciblage des cellules immunitaires
    Patrick Chames, Thierry Wurch
    médecine/sciences.2019; 35(12): 1072.     CrossRef
  • Emerging trends in bispecific antibody and scaffold protein therapeutics
    Petra Verdino, Shane Atwell, Stephen J Demarest
    Current Opinion in Chemical Engineering.2018; 19: 107.     CrossRef
  • Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
    Sarah Cooley, Peter Parham, Jeffrey S. Miller
    Blood.2018; 131(10): 1053.     CrossRef
  • Bispecific antibodies in cancer immunotherapy
    Eva Dahlén, Niina Veitonmäki, Per Norlén
    Therapeutic Advances in Vaccines and Immunotherapy.2018; 6(1): 3.     CrossRef
  • Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics
    Martin Dalziel, Stephen A Beers, Mark S Cragg, Max Crispin
    Glycobiology.2018; 28(9): 697.     CrossRef
  • The role of CD133 in cancer: a concise review
    Paige M. Glumac, Aaron M. LeBeau
    Clinical and Translational Medicine.2018;[Epub]     CrossRef
  • Advances and challenges in therapeutic monoclonal antibodies drug development
    Mariana Lopes dos Santos, Wagner Quintilio, Tania Maria Manieri, Lilian Rumi Tsuruta, Ana Maria Moro
    Brazilian Journal of Pharmaceutical Sciences.2018;[Epub]     CrossRef
  • Redirecting T cells to hematological malignancies with bispecific antibodies
    Mireya Paulina Velasquez, Challice L. Bonifant, Stephen Gottschalk
    Blood.2018; 131(1): 30.     CrossRef
  • Developmental and Functional Control of Natural Killer Cells by Cytokines
    Yang Wu, Zhigang Tian, Haiming Wei
    Frontiers in Immunology.2017;[Epub]     CrossRef
  • Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
    Zachary B. Davis, Daniel A. Vallera, Jeffrey S. Miller, Martin Felices
    Seminars in Immunology.2017; 31: 64.     CrossRef
  • 14,287 View
  • 787 Download
  • 67 Web of Science
  • 65 Crossref
Close layer
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae-Yong Kim, Yu Jung Kim, Sae-Won Han, Eunyoung Kang, Eun-Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong-Young Noh, Maria Lee, Hee Seung Kim, Seock-Ah Im, Jee Hyun Kim
Cancer Res Treat. 2017;49(4):1153-1163.   Published online February 27, 2017
DOI: https://doi.org/10.4143/crt.2016.463
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods
We retrospectively analyzed data of 66 premenopausal patients with hormone receptor– positive, human epidermal growth factor receptor 2–negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results
The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion
Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.

Citations

Citations to this article as recorded by  
  • Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study
    Yifei Chen, Ruyan Zhang, Ying Yan, Huiping Li, Guohong Song
    Breast Cancer Research and Treatment.2024; 206(3): 543.     CrossRef
  • Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
    Fatima Khan, Kristin Rojas, Matthew Schlumbrecht, Patricia Jeudin
    Current Oncology.2023; 30(2): 1794.     CrossRef
  • Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study
    Dwi Ris Andriyanto, Prihantono, Salman Ardi Syamsu, Muhammad Ihwan Kusuma, Joko Hendarto, Indra, Nilam Smaradania, Elridho Sampepajung, Asrul Mappiwali, Muhammad Faruk
    Annals of Medicine & Surgery.2022;[Epub]     CrossRef
  • Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis
    Joana Correia Oliveira, Filipa Costa Sousa, Inês Gante, Margarida Figueiredo Dias
    Medicina.2021; 57(4): 385.     CrossRef
  • Long-term effect of repeated deslorelin acetate treatment in bitches for reproduction control
    Brändli SP, Palm J, Kowalewski MP, Reichler IM
    Theriogenology.2021; 173: 73.     CrossRef
  • Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
    Gebra Cuyún Carter, Maitreyee Mohanty, Keri Stenger, Claudia Morato Guimaraes, Shivaprasad Singuru, Pradeep Basa, Sheena Singh, Vanita Tongbram, Sherko Kuemmel, Valentina Guarneri, Sara M Tolaney
    Cancer Management and Research.2021; Volume 13: 6537.     CrossRef
  • Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results
    Islam H. Metwally, Omar Hamdy, Saleh S. Elbalka, Mohamed Elbadrawy, Dina M. Elsaid
    Indian Journal of Surgical Oncology.2019; 10(3): 542.     CrossRef
  • Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
    Aditya Bardia, Sara Hurvitz
    Clinical Cancer Research.2018; 24(21): 5206.     CrossRef
  • 12,374 View
  • 360 Download
  • 10 Web of Science
  • 8 Crossref
Close layer
Practice Patterns Regarding Multidisciplinary Cancer Management and Suggestions for Further Refinement: Results from a National Survey in Korea
Yun-Gyoo Lee, Sukjoong Oh, Heejin Kimm, Dong-Hoe Koo, Do Yeun Kim, Bong-Seog Kim, Seung-Sei Lee
Cancer Res Treat. 2017;49(4):1164-1169.   Published online February 22, 2017
DOI: https://doi.org/10.4143/crt.2016.517
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to explore the process and operation of a cancer multidisciplinary team (MDT) after the reimbursement decision in Korea, and to identify ways to overcome the major barriers to effective and sustainable MDTs.
Materials and Methods
Approximately 1,000 cancer specialists, including medical oncologists, surgical oncologists, radiation oncologists, pathologists, and radiologists in general hospitals in Koreawere invited to complete the survey. The questionnaire covered the following topics: organizational structure of MDTs, candidates for consulting, the clinical decision-making initiative, and responsibility for dealing with legal disputes.
Results
We collected a total of 179 responses (18%) from physicians at institutions where an MDT approachwas active. A surgical oncologist (91%), internist (90%),radiologist (89%),radiation oncologist (86%), pathologist (71%), and trainees (20%) regularly participated in MDT operations. Approximately 55% of respondents stated that MDTs met regularly. In cases of a split opinion, the physician in charge (69%) or chairperson (17%) made the final decision, and most (86%) stated they followed the final decision. About 15% and 32% of respondents were “very satisfied” and “satisfied,” respectively, with the current MDT’s operations. Among 38 institutional representatives, 34% responded that the MDT operation became more active and 18% stated an MDT was newly implemented after the reimbursement decision.
Conclusion
The reimbursement decision invigorated MDT operations in almost half of eligible hospitals. Dissatisfaction regarding current MDTs was over 50%, and the high discordance rates regarding risk sharing suggest that it is necessary to revise the current system of MDTs.

Citations

Citations to this article as recorded by  
  • The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer
    Janneke E.W. Walraven, Theodora M. Ripping, Jorg R. Oddens, Bas W.G. van Rhijn, Catharina A. Goossens‐Laan, Maarten C.C.M. Hulshof, Lambertus A. Kiemeney, J.A. Witjes, Valery E.P.P. Lemmens, Jacobus J.M. van der Hoeven, Ingrid M.E. Desar, Katja K.H. Aben,
    BJU International.2023; 131(2): 244.     CrossRef
  • Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
    Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hyo Jung Kim, Hwan Jung Yun
    Cancers.2023; 15(2): 471.     CrossRef
  • Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review
    Janneke E. W. Walraven, Olga L. van der Hel, J. J. M. van der Hoeven, Valery E. P. P. Lemmens, Rob H. A. Verhoeven, Ingrid M. E. Desar
    BMC Health Services Research.2022;[Epub]     CrossRef
  • Understanding the Complexity, Underlying Processes, and Influencing Factors for Optimal Multidisciplinary Teamwork in Hospital-Based Cancer Teams
    Melissa Horlait, Saskia Baes, Melissa De Regge, Mark Leys
    Cancer Nursing.2021; 44(6): E476.     CrossRef
  • Experiences and Perceptions of Gender Discrimination and Equality among Korean Surgeons: Results of a Survey of the Korean Surgical Society
    Jihyeon Choi, Jeong-Eun Lee, Bora Choi, Jungook Kim, Seung Eun Lee
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Practice patterns of multidisciplinary team meetings in Korean cancer care and patient satisfaction with this approach
    Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Seungtaek Lim, Bong-Seog Kim, Do Yeun Kim
    The Korean Journal of Internal Medicine.2020; 35(1): 205.     CrossRef
  • Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
    Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
    BMC Cancer.2020;[Epub]     CrossRef
  • Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study
    Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee
    PLOS ONE.2019; 14(10): e0223678.     CrossRef
  • 7,946 View
  • 187 Download
  • 8 Web of Science
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP